{ "meta": { "batch_id": "SYN-GLP1-W28-XAI", "batch_index": 0, "batch_label": "Weekly batch · Jul 7–13, 2026", "xai_mode": "full_agent", "xai_label": "Full agent XAI", "clinic": "Synthetic GLP-1 / weight-management cohort", "encounters_reviewed": 200, "encounters_with_any_flag": 85, "flagged_in_queue": 12, "rules_version": "glp1-rules-v1.0", "agent_model": "composer-2.5", "xai_run_id": "xai_20260720T191036Z", "dataset": "RubikMD/data/synthetic/encounters.json", "generated_at": "2026-07-20T19:10:36.452552+00:00", "disclaimer": "Synthetic demo data only. Not PHI. Flags and reasoning come from the RubikMD hybrid detector (rules + Cursor SDK agent) on labeled synthetic charts. Method development / software verification — not clinical validation. Oversight assist; not diagnosis.", "liability_preloaded": true, "liability_model": "x-ai/grok-4.5", "liability_harness": "openrouter-direct", "liability_embedded_at": "2026-07-21T07:55:20.990Z" }, "cases": [ { "id": "SYN-0005", "priority": "high", "title": "BMI below label eligibility", "full_message": "BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity)", "patient_label": "Male, 40", "visit_date": "2026-07-09", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly", "flag_code": "E_BMI_BELOW_THRESHOLD", "rule_id": "R11", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "guideline_quote": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid...", "source_snippet": "40yo M on GLP-1 for weight management, BMI 24.7", "evidence_field": "Agent evidence", "evidence_raw": "vitals.bmi=24.7; note: '40yo M on GLP-1 for weight management, BMI 24.7'; assessment: 'Obesity with type 2 diabetes' [2]", "evidence_label": "vitals.bmi=24.7; note: '40yo M on GLP-1 for weight management, BMI 24.7'; assessment: 'Obesity with type 2 diabetes' [2]", "why": "BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity)", "note": "Encounter SYN-0005\nPatient: Male, 40 · BMI 24.7\nComorbidities: hypertension\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: Zepbound / Mounjaro (tirzepatide), 2.5 mg weekly (new start)\nLabs: HbA1c 8.1; eGFR 78\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nNew-start visit. 40yo M on GLP-1 for weight management, BMI 24.7. On Zepbound (tirzepatide) 2.5 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 8.1%, eGFR 78, ALT 29, TSH 3.16. Informed consent for GLP-1 therapy obtained and documented. Reports constipation; counseled on management. Follow-up scheduled in 42 days.\n\nAssessment\nObesity with type 2 diabetes, on GLP-1 therapy.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:09:42.100Z", "independent_summary": "Zepbound was started for weight management at BMI 24.7, below labeled eligibility thresholds.", "reasoning_trace": [ "Reviewed MTC/MEN2, pancreatitis, pregnancy (male), insulin/sulfonylurea interaction, consent, baseline labs, prior attempts, follow-up, titration, and compounded-product items—each documented or not applicable; no flags.", "Identified BMI 24.7 with weight-management initiation as below FDA Zepbound chronic weight-management thresholds despite hypertension [2].", "Did not flag missing HbA1c, renal function, BMI data, consent, MEN2 screen, follow-up, or pregnancy status because those elements are present or inapplicable.", "Did not flag E_INSULIN_INTERACTION or E_EATING_DISORDER_HISTORY because neither concurrent insulin/sulfonylurea nor eating-disorder history appears in the chart.", "reference_context [1] and [3] were not needed beyond [2] for the eligibility determination." ], "reasoning_steps": [ "Observed: Structured BMI is 24.7 and the note documents initiating Zepbound today for weight management with hypertension as the only listed comorbidity.", "Source: FDA Zepbound labeling requires obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity for chronic weight management [2].", "Gap: At BMI 24.7 the patient does not meet either labeled BMI threshold even with hypertension; the assessment labels 'Obesity' despite sub-threshold BMI.", "Conclusion: Starting branded weight-management therapy below labeled BMI criteria is an objective eligibility mismatch warranting medical director review, not a treatment recommendation." ], "agent_message": "BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity)", "agent_evidence": "vitals.bmi=24.7; note: '40yo M on GLP-1 for weight management, BMI 24.7'; assessment: 'Obesity with type 2 diabetes' [2]", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." }, { "n": 3, "title": "FDA label (tirzepatide) - Indications And Usage [part 2] (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with..." } ], "kb_cited": [ { "n": 2, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." } ], "all_agent_flags": [ { "error_code": "E_BMI_BELOW_THRESHOLD", "severity": "high", "message": "BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity)", "evidence": "vitals.bmi=24.7; note: '40yo M on GLP-1 for weight management, BMI 24.7'; assessment: 'Obesity with type 2 diabetes' [2]", "reasoning_steps": [ "Observed: Structured BMI is 24.7 and the note documents initiating Zepbound today for weight management with hypertension as the only listed comorbidity.", "Source: FDA Zepbound labeling requires obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity for chronic weight management [2].", "Gap: At BMI 24.7 the patient does not meet either labeled BMI threshold even with hypertension; the assessment labels 'Obesity' despite sub-threshold BMI.", "Conclusion: Starting branded weight-management therapy below labeled BMI criteria is an objective eligibility mismatch warranting medical director review, not a treatment recommendation." ] } ], "rules_codes": [ "E_BMI_BELOW_THRESHOLD" ] }, "liability_pack": { "flag": { "request_id": "SYN-0005", "error_code": "E_BMI_BELOW_THRESHOLD", "message": "BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity)", "evidence": "vitals.bmi=24.7; note: '40yo M on GLP-1 for weight management, BMI 24.7'; assessment: 'Obesity with type 2 diabetes' [2]", "note_excerpt": "40yo M on GLP-1 for weight management, BMI 24.7", "clinical_brief": "Zepbound was started for weight management at BMI 24.7, below labeled eligibility thresholds.", "clinical_title": "BMI below label eligibility", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly" }, "liability": { "request_id": "SYN-0005", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution — FDA Warning Letter 715883", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Shows FDA enforcement attention on tirzepatide-related products offered outside approved channels; used only to frame regulatory sensitivity around GLP-1 products, not as a BMI-eligibility holding for this clinic [2].", "used_part": "FDA reviewed website content and observed offers of compounded drug products including retatrutide, semaglutide and tirzepatide; retatrutide products described as unapproved new drugs and misbranded drugs in interstate commerce.", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "Bjorklund v. Novo Nordisk A/S", "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "date": "2024-02-05", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Illustrates active federal personal-injury docket activity involving GLP-1 manufacturers; relevant only as qualitative public-litigation context, not as evidence of clinic liability for BMI screening [3].", "used_part": "E.D. Pennsylvania diversity personal-injury docket 2:24-cv-00533 naming Novo Nordisk entities and Eli Lilly & Co.; memorandum in opposition to motion to dismiss filed.", "citation_tag": "[3]" }, { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation (MDL docket activity)", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Documents MDL-style consolidation activity for GLP-1 RA product-liability claims against manufacturers; cited to note manufacturer-side mass-tort posture only, distinct from clinic eligibility documentation [4].", "used_part": "Transfer order / streamlined docket materials reflecting Judicial Panel on Multidistrict Litigation transfer of GLP-1 RA NAION product-liability actions to the Eastern District of Pennsylvania.", "citation_tag": "[4]" } ], "executive_summary": "This oversight brief concerns initiation of branded tirzepatide (Zepbound) for weight management at a documented BMI of 24.7, below labeled chronic weight-management eligibility thresholds. Public materials supplied in the reference corpus address GLP-1 compounding and manufacturing enforcement and manufacturer-side product-liability dockets, not clinic-level BMI eligibility determinations. No settlement, verdict, or civil-penalty amounts tied to below-threshold BMI prescribing appear in the retrieved records. The public-record signal for this visit-level eligibility mismatch is therefore limited and does not establish liability as to this clinic or encounter. Director-level documentation review of indication, BMI, and comorbidity coding is the appropriate internal framing.", "director_summary": "This oversight brief concerns initiation of branded tirzepatide (Zepbound) for weight management at a documented BMI of 24.7, below labeled chronic weight-management eligibility thresholds. Public materials supplied in the reference corpus address GLP-1 compounding and manufacturing enforcement and manufacturer-side product-liability dockets, not clinic-level BMI eligibility determinations. No settlement, verdict, or civil-penalty amounts tied to below-threshold BMI prescribing appear in the retrieved records. The public-record signal for this visit-level eligibility mismatch is therefore limited and does not establish liability as to this clinic or encounter. Director-level documentation review of indication, BMI, and comorbidity coding is the appropriate internal framing.", "report": { "matter": "Zepbound initiation at BMI 24.7 — below labeled weight-management eligibility", "scope": "Review limited to this visit’s clinical concern (BMI below eligibility threshold for Zepbound weight management) and the vetted public authorities in reference_context (FDA warning letters, openFDA recall, CourtListener dockets/opinions). No clinic files, full label archive, or external research beyond those materials.", "facts_considered": "Structured vitals report BMI 24.7. Note excerpt: 40-year-old male on GLP-1 for weight management, BMI 24.7. Medication documented as Zepbound/Mounjaro (tirzepatide) 2.5 mg weekly. Message states BMI 24.7 is below Zepbound weight-management eligibility (≥30, or ≥27 with comorbidity). Evidence also records an assessment label of ‘Obesity with type 2 diabetes’ alongside the sub-threshold BMI. Reasoning notes hypertension as a listed comorbidity and identifies an objective mismatch between documented BMI and labeled chronic weight-management BMI criteria.", "issue_presented": "Whether initiation of branded tirzepatide for chronic weight management at a documented BMI below labeled eligibility thresholds, with an assessment still characterizing obesity, presents a process and documentation oversight issue when viewed against public regulatory and litigation patterns in the GLP-1 space.", "analysis": "The supplied clinical concern is an eligibility and documentation mismatch: branded Zepbound was started for weight management at BMI 24.7, which the concern materials state does not meet labeled thresholds of BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Public authorities in the corpus do not reproduce the Zepbound prescribing information itself; they instead reflect adjacent GLP-1 enforcement and litigation themes. FDA warning correspondence to an online seller of compounded retatrutide, semaglutide, and tirzepatide products emphasizes unapproved new drug and misbranding concerns for products offered outside the approved pathway [2]. That letter is regulatory enforcement against a compounder/seller, not a holding on clinic BMI screening, but it illustrates heightened federal attention to how tirzepatide-related products are positioned and distributed [2].\n\nSeparately, federal docket activity includes personal-injury and product-liability proceedings involving GLP-1 receptor agonists and manufacturers, including a diversity personal-injury matter naming Novo Nordisk entities [3] and multidistrict litigation activity concerning GLP-1 RAs and non-arteritic anterior ischemic optic neuropathy claims against manufacturers including Eli Lilly [4]. Those matters are manufacturer product-liability vehicles; they are not findings against prescribing clinics and do not address BMI eligibility thresholds for Zepbound initiation. An older district-court summary-judgment opinion in incretin-related litigation likewise concerns manufacturer product-liability theories, not clinic credentialing or eligibility screening [5].\n\nAccordingly, the public corpus supports only a qualitative observation that GLP-1 products sit in an active enforcement and mass-tort environment. It does not supply a public-record template equating below-threshold BMI prescribing with clinic liability, nor does it state dollar exposures for that fact pattern. The oversight value of the authorities is contextual: documentation that clearly reconciles indication, BMI, comorbidities, and product selection is the process theme implicated by this visit’s facts, without any determination that this clinic breached a duty.", "observations": [ "[1] Public FDA warning activity in the corpus targets compounded or overseas GLP-1-related drug operations (unapproved/misbranded products and CGMP concerns), not branded Zepbound BMI eligibility at the point of care [1][2].", "[2] CourtListener docket materials reflect ongoing manufacturer-focused GLP-1 personal-injury and MDL product-liability activity, which is categorically distinct from clinic malpractice or eligibility-screening claims [3][4].", "[3] No retrieved public record states a settlement, verdict, fine, or penalty amount for initiating tirzepatide below labeled BMI thresholds in a clinic setting.", "[4] An openFDA recall entry in the corpus concerns temperature abuse of Wegovy during distribution, an upstream supply-chain issue unrelated to BMI eligibility documentation [6]." ], "limitations": "This memorandum does not prove that the clinic violated labeling, committed malpractice, or will face claims. It does not authenticate the full FDA prescribing information, the complete chart, comorbidity workup, prior BMI trajectory, payer criteria, or informed-consent discussion. Manufacturer warning letters, recalls, and product-liability dockets are not adjudications about this visit. Absence of public dollar figures is not evidence that exposure is zero; it means the retrieved corpus simply does not state such figures for this fact pattern.", "director_considerations": "Consider whether the chart clearly documents the intended indication (chronic weight management versus another labeled use), the measured BMI proximate to initiation, and how any comorbidity list supports or does not support labeled overweight criteria. Consider reconciling the assessment term ‘Obesity’ with a recorded BMI of 24.7 to reduce internal inconsistency. Consider a structured eligibility checklist or second-review flag when BMI is below commonly referenced weight-management thresholds before branded therapy is started. These are documentation and process-review considerations only; they are not legal advice or treatment directives.", "risk_band": "limited" }, "exposure": { "summary": "Retrieved public records place GLP-1 products in an active manufacturer product-liability and FDA enforcement environment, including compounding-related warning letters and MDL docket activity. None of the supplied authorities states a settlement, verdict, award, fine, or civil penalty for clinic initiation of Zepbound below BMI eligibility thresholds. No public dollar exposure figure is therefore available for this concern. Qualitative analogy to manufacturer mass-tort dockets should not be read as a clinic loss estimate.", "figures": [], "basis": "Analogical context only from FDA warning letters on compounded GLP-1 offerings [2], manufacturer personal-injury and NAION-related GLP-1 docket activity [3][4], an older incretin product-liability opinion [5], and an unrelated Wegovy distribution recall [6]. No record supplies monetary dispositions for below-threshold BMI prescribing.", "confidence": "none", "transparency_note": "No public settlement, verdict, fine, or civil-penalty amounts appear in reference_context for BMI-below-eligibility prescribing or for any clinic-level tirzepatide eligibility mismatch. Figures are therefore empty. Filing fees and manufacturer MDL presence are not used as proxies for this clinic’s expected loss." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:03.469Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Bjorklund v. Novo Nordisk A/S", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "body": "Bjorklund v. Novo Nordisk A/S\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:24-cv-00533\nFiled: 2024-02-05\nCause: 28:1332 Diversity-Personal Injury Parties: ELI LILLY & CO; NOVO NORDISK A/S; Novo Nordisk U S Commercial Holdings Inc; Jaclyn Bjorklund; NOVO NORDISK INC.; NOVO NORDISK RESEARCH CENTER SEATTLE INC.; Novo Nordisk U S Holdings Inc; NOVO NORDISK NORTH AMERICA OPERATIONS A/S; Novo Nordisk Pharmaceutical Industries L P Filing: MEMORANDUM in Opposition re 73 MOTION to Dismiss for Lack of Jurisdiction or in the Alternative to Dismiss Plaintiff's Express Warranty Claim Pursuant to Rule 12(b)(6) MOTION to Dismiss For Failure to State a Claim filed by Jaclyn Bjorklund. (Attachments: # 1 Exhibit Exhibit List, # 2 Exhibit 1- Plaintiffs Declaration, # 3 Exhibit 2- Novo Nordisk A/S Company Profile, Bloomberg, # 4 Exhibit 3- Novo Nordisk A/S, 2022 Annual Report, # 5 Exhibit 4- Novo List" }, { "n": 4, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "FDA recall D-0393-2025: Cardinal Health Inc.", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0393-2025: Cardinal Health Inc.\nWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released." } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0008", "priority": "high", "title": "Insulin / secretagogue interaction risk", "full_message": "New GLP-1 start with concurrent basal insulin; no insulin dose reduction or hypoglycemia mitigation documented", "patient_label": "Female, 40", "visit_date": "2026-07-11", "medication": "Wegovy / Ozempic (semaglutide) 0.25 mg weekly", "flag_code": "E_INSULIN_INTERACTION", "rule_id": "agent", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label: Drug Interactions: concomitant insulin/secretagogue raises hypoglycemia risk (UNCOVERED by current rules).", "guideline_quote": "FDA label: Drug Interactions: concomitant insulin/secretagogue raises hypoglycemia risk (UNCOVERED by current rules).", "source_snippet": "New-start visit", "evidence_field": "Agent evidence", "evidence_raw": "history.comorbidities=['on insulin therapy']; doctor_report.note_text: 'Concurrent basal insulin therapy'", "evidence_label": "history.comorbidities=['on insulin therapy']; doctor_report.note_text: 'Concurrent basal insulin therapy'", "why": "New GLP-1 start with concurrent basal insulin; no insulin dose reduction or hypoglycemia mitigation documented", "note": "Encounter SYN-0008\nPatient: Female, 40 · BMI 27.0\nComorbidities: on insulin therapy\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Wegovy / Ozempic (semaglutide), 0.25 mg weekly (new start)\nLabs: HbA1c 5.3; eGFR 80\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nNew-start visit. 40yo F on GLP-1 for weight management, BMI 27.0. On Wegovy (semaglutide) 0.25 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Pregnancy status reviewed; not pregnant, contraception discussed. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 5.3%, eGFR 80, ALT 33, TSH 2.62. Informed consent for GLP-1 therapy obtained and documented. Concurrent basal insulin therapy. Reports nausea; counseled on management. Follow-up scheduled in 28 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "agent", "model": "composer-2.5", "run_at": "2026-07-20T19:09:22.567Z", "independent_summary": "Concurrent basal insulin at GLP-1 initiation without documented hypoglycemia-risk mitigation warrants medical director review.", "reasoning_trace": [ "Walked high-severity omissions: MTC/MEN2 screening and pregnancy status are documented in the note; structured fields show no MTC/MEN2/pancreatitis history — no E_CONTRAINDICATION_MTC, E_NO_MEN2_SCREEN, E_PANCREATITIS_HISTORY, or E_MISSING_PREGNANCY_STATUS.", "Structured labs include HbA1c 5.3% and eGFR 80; note confirms review — no E_MISSING_BASELINE_HBA1C or E_MISSING_RENAL.", "New start at 0.25 mg (not escalation); follow-up in 28 days scheduled — no E_RAPID_TITRATION, E_DOSE_ESCALATION_NO_FOLLOWUP, or E_NO_FOLLOWUP_PLAN.", "BMI 27 with documented prior weight-loss attempts and consent; FDA-approved Wegovy — no E_BMI_BELOW_THRESHOLD, E_MISSING_BMI, E_MISSING_PRIOR_ATTEMPTS, E_NO_CONSENT, or E_COMPOUNDED_NO_DISCLOSURE.", "No eating-disorder history in chart — E_EATING_DISORDER_HISTORY not flagged.", "Flagged E_INSULIN_INTERACTION because insulin co-therapy is documented without dose-reduction or hypoglycemia mitigation; reference_context [2] supports hypoglycemia concern; [1] and [3] were not needed for this flag." ], "reasoning_steps": [ "Observed: Structured history lists 'on insulin therapy' and the note confirms 'Concurrent basal insulin therapy' while initiating semaglutide 0.25 mg weekly.", "Source: Knowledge card — hypoglycemia risk rises when GLP-1 is combined with insulin or a sulfonylurea; consider reducing those agents [2].", "Gap: The plan documents continuation per titration schedule and nausea counseling but does not note insulin dose adjustment, hypoglycemia counseling, or glucose monitoring.", "Conclusion: Concurrent GLP-1 plus insulin is a defensible director-review item for hypoglycemia risk management, not a treatment directive." ], "agent_message": "New GLP-1 start with concurrent basal insulin; no insulin dose reduction or hypoglycemia mitigation documented", "agent_evidence": "history.comorbidities=['on insulin therapy']; doctor_report.note_text: 'Concurrent basal insulin therapy'", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "FDA label (tirzepatide) - Warnings And Cautions [part 9] (FDA label §warnings_and_cautions; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "5.7 Hypoglycemia ZEPBOUND lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes mellitus and BMI ≥27 kg/m 2 (Study 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 4.2% of ZEPBOUND-treated patients versus 1.3% of placebo-treated patients. In this..." }, { "n": 3, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_INSULIN_INTERACTION", "severity": "high", "message": "New GLP-1 start with concurrent basal insulin; no insulin dose reduction or hypoglycemia mitigation documented", "evidence": "history.comorbidities=['on insulin therapy']; doctor_report.note_text: 'Concurrent basal insulin therapy'", "reasoning_steps": [ "Observed: Structured history lists 'on insulin therapy' and the note confirms 'Concurrent basal insulin therapy' while initiating semaglutide 0.25 mg weekly.", "Source: Knowledge card — hypoglycemia risk rises when GLP-1 is combined with insulin or a sulfonylurea; consider reducing those agents [2].", "Gap: The plan documents continuation per titration schedule and nausea counseling but does not note insulin dose adjustment, hypoglycemia counseling, or glucose monitoring.", "Conclusion: Concurrent GLP-1 plus insulin is a defensible director-review item for hypoglycemia risk management, not a treatment directive." ] } ], "rules_codes": [] }, "liability_pack": { "flag": { "request_id": "SYN-0008", "error_code": "E_INSULIN_INTERACTION", "message": "New GLP-1 start with concurrent basal insulin; no insulin dose reduction or hypoglycemia mitigation documented", "evidence": "history.comorbidities=['on insulin therapy']; doctor_report.note_text: 'Concurrent basal insulin therapy'", "note_excerpt": "New-start visit", "clinical_brief": "Concurrent basal insulin at GLP-1 initiation without documented hypoglycemia-risk mitigation warrants legal counsel review.", "clinical_title": "Insulin / secretagogue interaction risk", "medication": "Wegovy / Ozempic (semaglutide) 0.25 mg weekly" }, "liability": { "request_id": "SYN-0008", "related": [], "executive_summary": "This oversight brief concerns a new-start semaglutide visit in which concurrent basal insulin is documented without a corresponding note of hypoglycemia-risk mitigation, dose adjustment, or monitoring counseling. The supplied public corpus contains FDA warning letters and manufacturer-facing GLP-1 product-liability dockets, none of which adjudicate clinic-level concurrent-insulin management or establish a documented standard of care for this visit. No public settlement, verdict, fine, or civil-penalty amounts in the retrieved materials address this process theme. Public-record signal for director oversight of this specific documentation gap is therefore insufficient. This memorandum does not assess liability and does not constitute legal advice.", "director_summary": "This oversight brief concerns a new-start semaglutide visit in which concurrent basal insulin is documented without a corresponding note of hypoglycemia-risk mitigation, dose adjustment, or monitoring counseling. The supplied public corpus contains FDA warning letters and manufacturer-facing GLP-1 product-liability dockets, none of which adjudicate clinic-level concurrent-insulin management or establish a documented standard of care for this visit. No public settlement, verdict, fine, or civil-penalty amounts in the retrieved materials address this process theme. Public-record signal for director oversight of this specific documentation gap is therefore insufficient. This memorandum does not assess liability and does not constitute legal advice.", "report": { "matter": "Insulin interaction risk — concurrent basal insulin at semaglutide (Wegovy/Ozempic) initiation", "scope": "Review limited to the supplied clinical concern (concurrent basal insulin at new GLP-1 start without documented hypoglycemia-risk mitigation) and the vetted public reference_context items only (FDA warning letters and CourtListener dockets/opinions). No clinic chart beyond the excerpt, no expert retention, and no external research.", "facts_considered": "Female patient, age 40, at a new-start visit on semaglutide 0.25 mg weekly (Wegovy/Ozempic). Structured history lists ‘on insulin therapy,’ and the clinician note states ‘Concurrent basal insulin therapy.’ The plan reflects continuation per titration schedule and nausea counseling. The supplied materials do not document insulin dose reduction, hypoglycemia counseling, or enhanced glucose monitoring at initiation.", "issue_presented": "Whether, for medical-director oversight purposes, initiation of a GLP-1 receptor agonist alongside documented concurrent basal insulin without charted hypoglycemia-risk mitigation presents a process and documentation vulnerability when viewed against publicly available regulatory and litigation patterns.", "analysis": "The clinical concern is narrow: concurrent basal insulin at GLP-1 initiation without documented mitigation of hypoglycemia risk. Public authorities in the reference set do not speak directly to that clinic-process issue. FDA warning letter activity in the corpus addresses overseas manufacturing deviations and website offerings of compounded or unapproved GLP-1-related products, not prescriber documentation of insulin co-administration or dose adjustment at a legitimate branded start [1][2].\n\nManufacturer-facing personal-injury and MDL dockets involving Novo Nordisk and related GLP-1 receptor agonist product-liability theories appear in the corpus, including a diversity personal-injury matter and a streamlined NAION products-liability MDL transfer posture [3][4]. Those filings concern product liability against manufacturers, not medical-malpractice or documentation standards for concurrent insulin management in ambulatory care. An older district-court summary-judgment opinion involving other diabetes therapies likewise does not establish a clinic duty or charting requirement for insulin adjustment at semaglutide start [5]. An unrelated insurer class-action appeal supplies no applicable standard [6].\n\nAccordingly, the public record supports only a general observation that GLP-1 products attract regulatory and product-liability attention. It does not supply a holding, consent decree, or enforcement narrative that maps onto the documentation gap described in this visit. Manufacturer product-liability activity is not interchangeable with clinic negligence exposure for this concern.", "observations": [ "[1] Public FDA warning-letter activity in the corpus targets manufacturing CGMP deviations and online compounded/unapproved GLP-1-related offerings, not clinic concurrent-insulin protocols.", "[2] Public dockets reflect manufacturer-directed GLP-1 product-liability and MDL activity (including personal-injury and NAION theories), which is a different liability channel from ambulatory documentation of hypoglycemia mitigation.", "[3] No retrieved public opinion or docket in this set articulates a holding on failure to reduce basal insulin or to counsel on hypoglycemia at GLP-1 initiation." ], "limitations": "This memorandum does not prove that the clinic departed from any standard of care, that hypoglycemia occurred or will occur, or that any claim has been or will be asserted. It does not evaluate the full medical record, prescribing rationale, prior insulin regimen, patient education outside the note excerpt, or manufacturer labeling relied upon at the visit. Public manufacturer dockets and FDA letters do not adjudicate this provider’s conduct. No finding of liability is made or implied.", "director_considerations": "Consider whether new-start GLP-1 templates prompt explicit documentation when history indicates concurrent insulin or secretagogue therapy, including any dose-adjustment decision, hypoglycemia counseling, and monitoring plan, or a brief rationale if no change is made. A targeted chart review sample of GLP-1 starts with insulin comorbidity flags may help assess documentation consistency. This is process-oversight commentary only, not legal advice or a treatment directive.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials reflect FDA enforcement correspondence regarding certain GLP-1-related manufacturing and compounded-product website conduct, and manufacturer-facing product-liability docket activity. None of those records states a settlement, verdict, award, fine, or civil penalty amount tied to clinic-level failure to mitigate insulin interaction risk at GLP-1 initiation. Qualitative analogy to manufacturer MDLs or compounding warning letters is weak for this ambulatory documentation concern and is not an estimate of clinic loss.", "figures": [], "basis": "No dollar figures for settlements, verdicts, fines, or penalties appear in the supplied reference_context items [1]–[6]. Exposure discussion is therefore limited to the absence of grounded public money figures and the non-equivalence of manufacturer product-liability dockets to clinic process risk on concurrent insulin.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, fine, or civil-penalty amounts for concurrent insulin/GLP-1 hypoglycemia-mitigation documentation failures at the clinic level. No clinic-specific exposure figure is known or inferred." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:05.329Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Bjorklund v. Novo Nordisk A/S", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "body": "Bjorklund v. Novo Nordisk A/S\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:24-cv-00533\nFiled: 2024-02-05\nCause: 28:1332 Diversity-Personal Injury Parties: ELI LILLY & CO; NOVO NORDISK A/S; Novo Nordisk U S Commercial Holdings Inc; Jaclyn Bjorklund; NOVO NORDISK INC.; NOVO NORDISK RESEARCH CENTER SEATTLE INC.; Novo Nordisk U S Holdings Inc; NOVO NORDISK NORTH AMERICA OPERATIONS A/S; Novo Nordisk Pharmaceutical Industries L P Filing: MEMORANDUM in Opposition re 73 MOTION to Dismiss for Lack of Jurisdiction or in the Alternative to Dismiss Plaintiff's Express Warranty Claim Pursuant to Rule 12(b)(6) MOTION to Dismiss For Failure to State a Claim filed by Jaclyn Bjorklund. (Attachments: # 1 Exhibit Exhibit List, # 2 Exhibit 1- Plaintiffs Declaration, # 3 Exhibit 2- Novo Nordisk A/S Company Profile, Bloomberg, # 4 Exhibit 3- Novo Nordisk A/S, 2022 Annual Report, # 5 Exhibit 4- Novo List" }, { "n": 4, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Holland v. Elevance Health, Inc.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10827843/holland-v-elevance-health-inc/", "body": "Holland v. Elevance Health, Inc.\nCourt: Court of Appeals for the First Circuit\nDocket: 25-1359\nFiled: 2026-03-27\nUnited States Court of Appeals For the First Circuit No. 25-1359 REBECCA HOLLAND, on her own behalf and on behalf of those similarly situated, Plaintiff, Appellant, v. ELEVANCE HEALTH, INC., f/k/a Anthem, Inc., Defendant, Appellee. APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MAINE" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0020", "priority": "high", "title": "Escalation without follow-up", "full_message": "Dose escalation documented without a scheduled follow-up visit", "patient_label": "Female, 48", "visit_date": "2026-07-12", "medication": "Wegovy / Ozempic (semaglutide) 1.7 mg weekly", "flag_code": "E_DOSE_ESCALATION_NO_FOLLOWUP", "rule_id": "R08", "rulebook": "clinic_protocol", "rulebook_label": "Clinic protocol", "source_cite": "FDA label dosing + clinic standard: monitoring visit accompanies escalation.", "guideline_quote": "FDA label dosing + clinic standard: monitoring visit accompanies escalation.", "source_snippet": "Escalating dose; 8 weeks on the prior dose", "evidence_field": "Agent evidence", "evidence_raw": "medication.is_dose_escalation=true; visit.follow_up_scheduled=false; doctor_report.note_text: 'No follow-up visit scheduled at this time.'", "evidence_label": "medication.is_dose_escalation=true; visit.follow_up_scheduled=false; doctor_report.note_text: 'No follow-up visit scheduled at this time.'", "why": "Dose escalation documented without a scheduled follow-up visit", "note": "Encounter SYN-0020\nPatient: Female, 48 · BMI 38.7\nComorbidities: dyslipidemia\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Wegovy / Ozempic (semaglutide), 1.7 mg weekly (escalation after 8 weeks on prior dose)\nLabs: HbA1c 5.8; eGFR 113\nFollow-up scheduled: no\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nFollow-up visit. 48yo F on GLP-1 for weight management, BMI 38.7. On Wegovy (semaglutide) 1.7 mg weekly. Escalating dose; 8 weeks on the prior dose. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Pregnancy status reviewed; not pregnant, contraception discussed. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 5.8%, eGFR 113, ALT 32, TSH 1.41. No new GI symptoms reported. No follow-up visit scheduled at this time.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:10:08.723Z", "independent_summary": "Dose escalation was performed without a scheduled follow-up visit despite contradictory plan documentation.", "reasoning_trace": [ "Reviewed eligibility: BMI 38.7 meets threshold; no MTC/MEN2, pancreatitis, or eating-disorder history documented.", "Confirmed pregnancy status addressed (patient.pregnant=false; note documents review and contraception discussion).", "Baseline/monitoring labs present (HbA1c 5.8%, eGFR 113); no concurrent insulin or sulfonylurea — E_INSULIN_INTERACTION not triggered.", "Titration interval appropriate at 8 weeks on prior dose — E_RAPID_TITRATION not flagged.", "Identified contradiction: plan states follow-up scheduled but note and visit fields show none after dose escalation — flagged E_DOSE_ESCALATION_NO_FOLLOWUP.", "reference_context [1]–[3] reviewed but not cited; no additional chart-supported flags from those excerpts." ], "reasoning_steps": [ "Observed: Semaglutide dose escalation is documented (medication.is_dose_escalation=true) after 8 weeks on the prior dose, but visit.follow_up_scheduled=false and the note states no follow-up visit was scheduled.", "Source: Knowledge card — monitoring/follow-up is expected, especially around dose changes; titration guidance emphasizes GI adverse-event risk during dose steps.", "Gap: Despite plan text stating 'Follow-up scheduled,' structured visit fields and the note body confirm no follow-up was actually scheduled after this escalation.", "Conclusion: Escalating GLP-1 dose without a defined follow-up interval leaves tolerability and safety monitoring unaddressed — a director-facing oversight concern, not a treatment diagnosis." ], "agent_message": "Dose escalation documented without a scheduled follow-up visit", "agent_evidence": "medication.is_dose_escalation=true; visit.follow_up_scheduled=false; doctor_report.note_text: 'No follow-up visit scheduled at this time.'", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 3, "title": "A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. (glp1-semaglutide §abstract; DOI 10.7759/cureus.107970)", "body": "Obesity is an increasingly growing public health issue affecting a substantial proportion of the population in the United States. This condition increases the risk for multiple disease processes, including cardiometabolic disorders, osteoarthritis, gout, respiratory issues, reproductive problems,..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_DOSE_ESCALATION_NO_FOLLOWUP", "severity": "high", "message": "Dose escalation documented without a scheduled follow-up visit", "evidence": "medication.is_dose_escalation=true; visit.follow_up_scheduled=false; doctor_report.note_text: 'No follow-up visit scheduled at this time.'", "reasoning_steps": [ "Observed: Semaglutide dose escalation is documented (medication.is_dose_escalation=true) after 8 weeks on the prior dose, but visit.follow_up_scheduled=false and the note states no follow-up visit was scheduled.", "Source: Knowledge card — monitoring/follow-up is expected, especially around dose changes; titration guidance emphasizes GI adverse-event risk during dose steps.", "Gap: Despite plan text stating 'Follow-up scheduled,' structured visit fields and the note body confirm no follow-up was actually scheduled after this escalation.", "Conclusion: Escalating GLP-1 dose without a defined follow-up interval leaves tolerability and safety monitoring unaddressed — a director-facing oversight concern, not a treatment diagnosis." ] } ], "rules_codes": [ "E_DOSE_ESCALATION_NO_FOLLOWUP" ] }, "liability_pack": { "flag": { "request_id": "SYN-0020", "error_code": "E_DOSE_ESCALATION_NO_FOLLOWUP", "message": "Dose escalation documented without a scheduled follow-up visit", "evidence": "medication.is_dose_escalation=true; visit.follow_up_scheduled=false; doctor_report.note_text: 'No follow-up visit scheduled at this time.'", "note_excerpt": "Escalating dose; 8 weeks on the prior dose", "clinical_brief": "Dose escalation was performed without a scheduled follow-up visit despite contradictory plan documentation.", "clinical_title": "Escalation without follow-up", "medication": "Wegovy / Ozempic (semaglutide) 1.7 mg weekly" }, "liability": { "request_id": "SYN-0020", "related": [ { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation (E.D. Pa.)", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Shows public aggregation of GLP-1 safety-related product claims against manufacturers; used only to note that product MDL activity is not a surrogate for clinic follow-up or titration-process standards on this visit [3].", "used_part": "Transfer order / streamlined docket caption for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation in E.D. Pennsylvania.", "citation_tag": "[3]" }, { "item_type": "warning_letter", "title": "GLP-1 Solution — FDA warning letter 715883", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Illustrates FDA enforcement attention to certain GLP-1-related drug offerings; cited solely as ambient regulatory context, not as authority on post-escalation clinic follow-up [2].", "used_part": "FDA reviewed website content offering compounded drug products including semaglutide and advised that specified products were unapproved new drugs and misbranded drugs introduced into interstate commerce.", "citation_tag": "[2]" }, { "item_type": "enforcement_recall", "title": "FDA recall D-0393-2025 — Wegovy temperature abuse", "url": "https://api.fda.gov/drug/enforcement.json", "date": "", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_OTHER" ], "relevance": "Confirms public enforcement visibility of Wegovy supply-chain quality events; used to distinguish distribution temperature abuse from the visit’s follow-up-scheduling concern [6].", "used_part": "Reason: Temperature abuse — Wegovy product potentially exposed to temperatures outside labeled storage conditions due to a shipping error; removed from refrigerated storage for an extended period and inappropriately released.", "citation_tag": "[6]" } ], "executive_summary": "This memorandum reviews a single visit concern involving documented semaglutide dose escalation without a scheduled follow-up, including contradictory plan language versus structured visit fields and the note body. The supplied public corpus contains FDA warning letters, a GLP-1 products-liability multidistrict docket, trademark litigation, an older pharmaceutical opinion, and a Wegovy distribution recall; none adjudicates clinic-level titration monitoring or follow-up scheduling duties. No public settlement, verdict, fine, or civil-penalty figures in the retrieved materials attach to failure to schedule post-escalation follow-up. Public-record support for quantifying exposure on this discrete process issue is therefore insufficient. The memorandum identifies documentation and oversight considerations only and does not assess liability for this clinic or visit.", "director_summary": "This memorandum reviews a single visit concern involving documented semaglutide dose escalation without a scheduled follow-up, including contradictory plan language versus structured visit fields and the note body. The supplied public corpus contains FDA warning letters, a GLP-1 products-liability multidistrict docket, trademark litigation, an older pharmaceutical opinion, and a Wegovy distribution recall; none adjudicates clinic-level titration monitoring or follow-up scheduling duties. No public settlement, verdict, fine, or civil-penalty figures in the retrieved materials attach to failure to schedule post-escalation follow-up. Public-record support for quantifying exposure on this discrete process issue is therefore insufficient. The memorandum identifies documentation and oversight considerations only and does not assess liability for this clinic or visit.", "report": { "matter": "Semaglutide dose escalation without scheduled follow-up (visit oversight)", "scope": "Review limited to this visit’s clinical_brief, message, evidence, note_excerpt, and reasoning_steps, together with the vetted public reference_context items [1]–[6] only. No chart beyond the supplied excerpt, no retention file, and no external research.", "facts_considered": "Female patient, age 48. Medication documented as Wegovy/Ozempic (semaglutide) 1.7 mg weekly. Evidence flags medication.is_dose_escalation=true after eight weeks on the prior dose (note_excerpt: “Escalating dose; 8 weeks on the prior dose”). visit.follow_up_scheduled=false. Doctor report note text states “No follow-up visit scheduled at this time.” Reasoning steps describe a gap between plan text asserting that follow-up was scheduled and structured fields plus the note body confirming no follow-up was scheduled after escalation.", "issue_presented": "Whether public authorities in the supplied corpus illuminate process and documentation risk when a GLP-1 dose is escalated without a defined follow-up interval, including internal inconsistency between plan language and actual scheduling fields—framed solely for medical-director oversight, not as a liability determination.", "analysis": "The clinical concern is narrow: escalation of semaglutide with express documentation that no follow-up visit was scheduled, despite contradictory plan wording elsewhere. Public items retrieved do not speak to that clinic-process question. FDA warning letter [1] addresses CGMP deviations at a foreign manufacturing facility and does not discuss outpatient titration or follow-up scheduling. Warning letter [2] concerns a website offering compounded GLP-1-related products as unapproved and misbranded drugs; it reflects enforcement posture toward certain compounded offerings, not a standard of care for post-escalation monitoring in a clinic visit.\n\nDocket [3] reflects centralized products-liability litigation involving GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy claims against a manufacturer. That docket illustrates that GLP-1 safety issues are the subject of aggregated federal product litigation, but manufacturer product-liability MDLs are not clinic malpractice actions and do not establish duties regarding scheduling follow-up after a dose step. Docket [4] is trademark/Lanham Act litigation by Novo Nordisk against a third party and is not instructive on visit follow-up. Opinion [5] is an older summary-judgment decision in multi-plaintiff pharmaceutical litigation against Merck and does not address semaglutide titration monitoring. Recall [6] concerns potential temperature abuse of Wegovy during distribution and likewise does not map to follow-up after dose escalation.\n\nAccordingly, the public corpus supplies ambient GLP-1 regulatory and product-litigation context at best. It does not furnish holdings, consent decrees, or enforcement narratives that evaluate failure to schedule follow-up at the time of dose escalation, nor does it resolve the internal documentation contradiction described in this visit’s evidence.", "observations": [ "[1] Public FDA warning letters in the corpus target manufacturing CGMP and online compounded GLP-1 product offerings, not outpatient dose-escalation follow-up workflows.", "[2] A streamlined MDL docket in the Eastern District of Pennsylvania aggregates GLP-1 RA NAION products-liability claims against a manufacturer, indicating sustained federal product litigation activity around GLP-1 safety themes without speaking to clinic scheduling practices [3].", "[3] An openFDA enforcement recall entry documents distribution-related temperature abuse of Wegovy pens, a supply-chain quality event distinct from clinical titration and follow-up documentation [6].", "[4] No retrieved public record states settlement, verdict, fine, or civil-penalty amounts tied to absence of scheduled follow-up after GLP-1 dose escalation." ], "limitations": "This memorandum does not prove that the clinic breached any duty, that the patient experienced harm, or that any claim has been or will be asserted. It does not reconstruct the full medical record, prescribing rationale, patient instructions, portal messaging, or informal follow-up arrangements outside the supplied fields. Public items [1]–[6] do not adjudicate this visit, do not equate manufacturer product litigation or compounding enforcement with clinic malpractice, and do not supply dollar exposure figures for this concern. Absence of a scheduled follow-up flag in structured data is taken as stated in the evidence only.", "director_considerations": "Consider reconciling plan-template language that asserts “follow-up scheduled” with structured scheduling fields and the contemporaneous note statement that no follow-up was scheduled. Consider whether dose-escalation encounters carry a consistent documentation expectation for the intended monitoring interval, tolerability check method, and responsible party, so that the chart reflects a single coherent plan. Any review should remain process- and documentation-focused; this memorandum offers no treatment or legal directive.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials do not state settlements, verdicts, awards, fines, or civil penalties for clinic-level dose escalation without scheduled follow-up. Ambient public activity includes manufacturer-focused GLP-1 products-liability consolidation and FDA actions on compounding and distribution quality, which are not interchangeable with malpractice exposure for this visit. No public dollar figure in the corpus can be grounded to this concern.", "figures": [], "basis": "Analogy reviewed against warning letters [1][2], GLP-1 NAION MDL docket [3], trademark docket [4], Seufert opinion [5], and Wegovy temperature-abuse recall [6]; none supplies monetary awards or penalties for the follow-up-scheduling issue presented.", "confidence": "none", "transparency_note": "No public settlement, verdict, fine, or civil-penalty amounts appear in reference_context for dose escalation without follow-up or analogous clinic monitoring failures. Figures are therefore empty. Qualitative MDL and FDA items are manufacturer-, compounding-, or distribution-centered and do not quantify clinic exposure for this visit." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:09.332Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "Novo Nordisk A/S v. DTG II, PLC", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/69011691/novo-nordisk-as-v-dtg-ii-plc/", "body": "Novo Nordisk A/S v. DTG II, PLC\nCourt: District Court, W.D. Michigan\nDocket: 1:24-cv-00799\nFiled: 2024-08-02\nCause: 15:1125 Trademark Infringement (Lanham Act) Parties: Novo Nordisk A/S; DTG II, PLC; Novo Nordisk Inc. Filing: complaint — Case 1:24-cv-00799-PLM-SJB ECF No. 1, PageID.1 Filed 08/02/24 Page 1 of 24 UNITED STATES DISTRICT COURT WESTERN DISTRICT OF MICHIGAN NOVO NORDISK A/S AND NOVO NORDISK INC., Plaintiffs, Case No. 1:24-cv-799 v. DTG II, PLC, d/b/a BEYONDMD, Defendant. Filing: Exhibit D - RYBELSUS registration — Case 1:24-cv-00799-PLM-SJB ECF No. 1-4, PagelD.37 Filed 08/02/24 Page 1 of 4 EXHIBIT D Case 1:24-cv-00799-PLM-SJB EC agelD.38 Filed 08/02/24 Page 2 of 4 TO ALL, TO WHOM THESE; PRESENTS; SHAUL, COME: UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office November 16, 2023 THE ATTACHED U.S. TRADEMARK REGISTRATION 5,682,853 IS CERTIFIED TO BE A T" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "FDA recall D-0393-2025: Cardinal Health Inc.", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0393-2025: Cardinal Health Inc.\nWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released." } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0023", "priority": "high", "title": "Missing baseline eGFR at start", "full_message": "New GLP-1 start without documented baseline renal function (eGFR)", "patient_label": "Male, 45", "visit_date": "2026-07-13", "medication": "Wegovy / Ozempic (semaglutide) 1.7 mg weekly", "flag_code": "E_MISSING_RENAL", "rule_id": "R06", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label: renal monitoring with GI-loss dehydration risk; baseline eGFR.", "guideline_quote": "FDA label: renal monitoring with GI-loss dehydration risk; baseline eGFR.", "source_snippet": "Baseline eGFR not documented at new start (HbA1c on chart: 6.1).", "evidence_field": "Agent evidence", "evidence_raw": "labs.egfr=null; note lists HbA1c 6.1%, ALT 28, TSH 1.58 but no eGFR/creatinine", "evidence_label": "labs.egfr=null; note lists HbA1c 6.1%, ALT 28, TSH 1.58 but no eGFR/creatinine", "why": "New GLP-1 start without documented baseline renal function (eGFR)", "note": "Encounter SYN-0023\nPatient: Male, 45 · BMI 40.7\nComorbidities: hypertension, dyslipidemia, NAFLD, OSA, history of eating disorder\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: Wegovy / Ozempic (semaglutide), 1.7 mg weekly (new start)\nLabs: HbA1c 6.1; eGFR not documented\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nFollow-up visit. 45yo M on GLP-1 for weight management, BMI 40.7. On Wegovy (semaglutide) 1.7 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 6.1%, ALT 28, TSH 1.58. Informed consent for GLP-1 therapy obtained and documented. History of an eating disorder. Reports constipation; counseled on management. Follow-up scheduled in 28 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:10:16.619Z", "independent_summary": "New semaglutide start lacks documented baseline renal function and does not address eating-disorder caution despite documented history.", "reasoning_trace": [ "Reviewed MTC/MEN2: screening documented in note; structured history negative — E_CONTRAINDICATION_MTC and E_NO_MEN2_SCREEN not flagged.", "Patient is 45-year-old male — pregnancy status not applicable; E_MISSING_PREGNANCY_STATUS not flagged.", "No pancreatitis history, no insulin/sulfonylurea, BMI 40.7, HbA1c present, consent and follow-up documented — related codes not flagged.", "Structured egfr is null with no renal labs in note on is_new_start=true — flagged E_MISSING_RENAL.", "Eating disorder in history/note without explicit caution plan — flagged E_EATING_DISORDER_HISTORY.", "Noted internal inconsistency (is_new_start=true, weeks_on_current_dose=8, note says 'Initiating therapy today') but no matching error_code; E_RAPID_TITRATION not flagged without clear titration evidence.", "reference_context excerpts [1]–[3] were not used; they do not address baseline renal monitoring or eating-disorder precautions." ], "reasoning_steps": [ "Observed: Structured labs show egfr=null; physician note reviews HbA1c, ALT, and TSH only with no renal function documented.", "Source: Knowledge card — new start workup requires baseline renal function (eGFR); GI fluid loss from GLP-1 can worsen renal function.", "Gap: No baseline eGFR/creatinine obtained or reviewed despite medication.is_new_start=true.", "Conclusion: Missing baseline renal assessment on a new GLP-1 start is a defensible safety/documentation gap for medical director review, not a diagnosis." ], "agent_message": "New GLP-1 start without documented baseline renal function (eGFR)", "agent_evidence": "labs.egfr=null; note lists HbA1c 6.1%, ALT 28, TSH 1.58 but no eGFR/creatinine", "kb_excerpts": [ { "n": 1, "title": "Association of GLP-1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation. (glp1-safety §abstract; DOI 10.1111/dom.70867)", "body": "Aims: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) initiation and adverse gastrointestinal, renal, respiratory and psychiatric outcomes among individuals with opioid use disorder (OUD). Materials and methods: This retrospective cohort study was conducted..." }, { "n": 2, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 3, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_MISSING_RENAL", "severity": "high", "message": "New GLP-1 start without documented baseline renal function (eGFR)", "evidence": "labs.egfr=null; note lists HbA1c 6.1%, ALT 28, TSH 1.58 but no eGFR/creatinine", "reasoning_steps": [ "Observed: Structured labs show egfr=null; physician note reviews HbA1c, ALT, and TSH only with no renal function documented.", "Source: Knowledge card — new start workup requires baseline renal function (eGFR); GI fluid loss from GLP-1 can worsen renal function.", "Gap: No baseline eGFR/creatinine obtained or reviewed despite medication.is_new_start=true.", "Conclusion: Missing baseline renal assessment on a new GLP-1 start is a defensible safety/documentation gap for medical director review, not a diagnosis." ] }, { "error_code": "E_EATING_DISORDER_HISTORY", "severity": "medium", "message": "Prior eating disorder documented; no explicit GLP-1 caution or monitoring plan noted", "evidence": "history.comorbidities includes 'history of eating disorder'; note: 'History of an eating disorder.'", "reasoning_steps": [ "Observed: Comorbidity list and note both document prior eating disorder; no active/remission status or ED-specific safety counseling is recorded.", "Source: Knowledge card — use caution with active or prior eating disorders when initiating weight-loss GLP-1 therapy.", "Gap: Note does not document risk discussion, remission status, or monitoring for ED recurrence with pharmacologic weight loss.", "Conclusion: Relative contraindication context is present but safety framing is absent — appropriate for director oversight, not a care grade." ] } ], "rules_codes": [ "E_MISSING_RENAL" ] }, "liability_pack": { "flag": { "request_id": "SYN-0023", "error_code": "E_MISSING_RENAL", "message": "New GLP-1 start without documented baseline renal function (eGFR)", "evidence": "labs.egfr=null; note lists HbA1c 6.1%, ALT 28, TSH 1.58 but no eGFR/creatinine", "note_excerpt": "Baseline eGFR not documented at new start (HbA1c on chart: 6.1).", "clinical_brief": "New semaglutide start lacks documented baseline renal function and does not address eating-disorder caution despite documented history.", "clinical_title": "Missing baseline eGFR at start", "medication": "Wegovy / Ozempic (semaglutide) 1.7 mg weekly" }, "liability": { "request_id": "SYN-0023", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution - 715883 - 09/09/2025", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_COMPOUNDING", "THEME_REGULATORY_ENFORCEMENT" ], "relevance": "Illustrates FDA enforcement posture toward unapproved/compounded semaglutide offerings; used only as general GLP-1 regulatory background, not as authority on clinic eGFR documentation. [2]", "used_part": "FDA reviewed website content offering compounded drug products including semaglutide and advised that retatrutide products are unapproved new drugs and misbranded drugs in interstate commerce.", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "Bjorklund v. Novo Nordisk A/S", "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "date": "2024-02-05", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_MALPRACTICE_NEGLIGENCE" ], "relevance": "Shows manufacturer-facing personal-injury docket activity involving Novo Nordisk entities; not a holding on clinic baseline renal screening and not applied as clinic liability. [3]", "used_part": "E.D. Pennsylvania docket 2:24-cv-00533, filed 2024-02-05, cause 28:1332 Diversity-Personal Injury, parties including Novo Nordisk entities and Jaclyn Bjorklund.", "citation_tag": "[3]" }, { "item_type": "enforcement_recall", "title": "FDA recall D-0393-2025: Cardinal Health Inc. (Wegovy)", "url": "https://api.fda.gov/drug/enforcement.json", "date": "", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_PRODUCT_LIABILITY" ], "relevance": "Confirms public enforcement attention to Wegovy handling/quality (temperature abuse); unrelated to missing eGFR but identifies product-channel risk themes around the same molecule. [5]", "used_part": "Wegovy (semaglutide) recalled for temperature abuse: product potentially exposed to temperatures outside labeled storage conditions due to a shipping error and inappropriately released.", "citation_tag": "[5]" } ], "executive_summary": "This oversight brief concerns a new semaglutide start in which baseline renal function (eGFR/creatinine) is not documented, while other labs appear on the chart. The supplied public corpus contains FDA warning letters, manufacturer-related dockets, and temperature-abuse recalls, none of which adjudicate clinic-level baseline renal screening or documentation duties for GLP-1 initiation. No public settlement, verdict, or civil-penalty figures tied to missing eGFR at start are stated in the retrieved records. Public-record signal for this specific documentation gap is therefore insufficient for exposure quantification. Director-level review may focus on whether baseline renal assessment is recorded before new GLP-1 therapy.", "director_summary": "This oversight brief concerns a new semaglutide start in which baseline renal function (eGFR/creatinine) is not documented, while other labs appear on the chart. The supplied public corpus contains FDA warning letters, manufacturer-related dockets, and temperature-abuse recalls, none of which adjudicate clinic-level baseline renal screening or documentation duties for GLP-1 initiation. No public settlement, verdict, or civil-penalty figures tied to missing eGFR at start are stated in the retrieved records. Public-record signal for this specific documentation gap is therefore insufficient for exposure quantification. Director-level review may focus on whether baseline renal assessment is recorded before new GLP-1 therapy.", "report": { "matter": "Missing baseline renal labs at new semaglutide start", "scope": "Review limited to the supplied clinical concern (missing baseline eGFR/creatinine on new Wegovy/Ozempic start; note documenting HbA1c, ALT, TSH only) and the public authorities in reference_context (FDA warning letters, court dockets, openFDA recalls).", "facts_considered": "Male, 45. Medication: Wegovy/Ozempic (semaglutide) 1.7 mg weekly as a new start. Structured labs show egfr=null. Physician note references HbA1c 6.1%, ALT 28, and TSH 1.58; baseline eGFR/creatinine is not documented. Clinical brief also notes eating-disorder caution history is not addressed. Reasoning identifies absence of baseline renal assessment on a new GLP-1 start as a documentation/safety-process gap for oversight, not a diagnosis.", "issue_presented": "Whether absence of documented baseline renal function at initiation of semaglutide presents a process and documentation oversight issue relative to publicly observable regulatory and litigation patterns around GLP-1 products.", "analysis": "The clinical concern is narrow: a new semaglutide start without documented baseline eGFR or creatinine, despite other metabolic labs on the chart. Public authorities retrieved do not speak directly to clinic standards for renal laboratory screening at GLP-1 initiation. FDA warning letter [2] addresses a foreign website offering compounded semaglutide and other unapproved GLP-1-related products and frames unapproved/misbranded drug distribution, not ambulatory baseline lab documentation. Docket [3] is a diversity personal-injury action naming Novo Nordisk entities; it reflects manufacturer-facing product litigation activity but does not establish clinic liability standards for missing eGFR. Recalls [5] and [6] concern temperature abuse of Wegovy and Ozempic in distribution/sample channels and likewise do not address prescriber renal workup.\n\nAccordingly, the cited materials supply only attenuated product- and supply-chain context for semaglutide generally. They do not supply holdings, consent decrees, or enforcement findings about failure to obtain or record baseline renal function before starting branded Wegovy/Ozempic in a clinic setting. Manufacturer product-liability and compounding-enforcement postures are not interchangeable with malpractice or screening-process claims against a treating clinic. On this corpus, public-pattern support for elevating this specific visit concern beyond a documentation/process flag is weak.", "observations": [ "[1] Public FDA warning activity in the corpus targets manufacturing deviations and online compounded/unapproved GLP-1 offerings, not clinic documentation of baseline eGFR.", "[2] At least one federal personal-injury docket names Novo Nordisk entities in connection with GLP-1 product litigation, indicating ongoing manufacturer-facing dispute activity without clinic screening holdings.", "[3] OpenFDA enforcement entries for Wegovy and Ozempic in the corpus relate to temperature abuse in distribution/sample handling, a supply-chain quality theme distinct from renal lab gaps at initiation." ], "limitations": "This memorandum does not prove that the clinic departed from any applicable standard of care, that the patient sustained renal injury, or that any claim has been or will be asserted. Public records cited do not evaluate this visit, this note, or this organization’s protocols. No finding of liability is made.", "director_considerations": "Consider whether the chart should reflect baseline eGFR/creatinine (or a documented clinical rationale if deferred) before or at new semaglutide start, and whether eating-disorder history flagged in the brief is acknowledged in the record. Internal audit may compare new GLP-1 starts for consistent renal lab documentation. No treatment or legal disposition is advised herein.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public records do not state settlement amounts, verdicts, fines, or civil penalties for missing baseline renal function documentation at semaglutide initiation. Analogous materials concern compounded/unapproved GLP-1 marketing, manufacturer personal-injury docket activity, and temperature-abuse recalls, which are not clinic malpractice exposure measures for this visit. No dollar exposure figure can be grounded for this concern from the corpus.", "figures": [], "basis": "No usable monetary awards or penalties in reference_context for missing eGFR/renal labs; qualitative context limited to FDA warning letter [2], docket [3], and recalls [5][6] as product/supply-chain background only.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, or fine amounts applicable to missing baseline renal labs at GLP-1 start. No dollar figures are available to report for this concern." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:00.341Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Bjorklund v. Novo Nordisk A/S", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "body": "Bjorklund v. Novo Nordisk A/S\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:24-cv-00533\nFiled: 2024-02-05\nCause: 28:1332 Diversity-Personal Injury Parties: ELI LILLY & CO; NOVO NORDISK A/S; Novo Nordisk U S Commercial Holdings Inc; Jaclyn Bjorklund; NOVO NORDISK INC.; NOVO NORDISK RESEARCH CENTER SEATTLE INC.; Novo Nordisk U S Holdings Inc; NOVO NORDISK NORTH AMERICA OPERATIONS A/S; Novo Nordisk Pharmaceutical Industries L P Filing: MEMORANDUM in Opposition re 73 MOTION to Dismiss for Lack of Jurisdiction or in the Alternative to Dismiss Plaintiff's Express Warranty Claim Pursuant to Rule 12(b)(6) MOTION to Dismiss For Failure to State a Claim filed by Jaclyn Bjorklund. (Attachments: # 1 Exhibit Exhibit List, # 2 Exhibit 1- Plaintiffs Declaration, # 3 Exhibit 2- Novo Nordisk A/S Company Profile, Bloomberg, # 4 Exhibit 3- Novo Nordisk A/S, 2022 Annual Report, # 5 Exhibit 4- Novo List" }, { "n": 4, "title": "Novo Nordisk A/S v. New England Weight Loss, LLC", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/69873291/novo-nordisk-as-v-new-england-weight-loss-llc/", "body": "Novo Nordisk A/S v. New England Weight Loss, LLC\nCourt: District Court, D. New Hampshire\nDocket: 1:25-cv-00141\nFiled: 2025-04-10\nCause: 15:1051 Trademark Infringement Parties: Novo Nordisk A/S; New England Weight Loss, LLC Filing: Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 11 Filed 10/17/25 Page 1 of 21 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 1:25-cv-00141-SE-AJ New England Weight Loss, LLC REPORT AND RECOMMENDATION Plaintiffs, Novo Nordisk A/S and Novo No Filing: Complaint - New Case Filing: Order on Motion for Default Judgment AND Order on Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 12 Filed 11/18/25 Page 1 of 2 UNITED STATES DISTRICT COURT DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 25-cv-141-SE-AJ New England Weight Loss, LLC ORDER N\nReport and Recommendation: Case 1:25" }, { "n": 5, "title": "FDA recall D-0393-2025: Cardinal Health Inc.", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0393-2025: Cardinal Health Inc.\nWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released." }, { "n": 6, "title": "FDA recall D-0617-2021: Novo Nordisk Inc", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0617-2021: Novo Nordisk Inc\nOZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit) Reason: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors." } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0026", "priority": "high", "title": "MTC / MEN2 history on GLP-1", "full_message": "Family history of medullary thyroid carcinoma documented while continuing tirzepatide dose escalation", "patient_label": "Female, 43", "visit_date": "2026-07-07", "medication": "Zepbound / Mounjaro (tirzepatide) 15.0 mg weekly", "flag_code": "E_CONTRAINDICATION_MTC", "rule_id": "R01", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label (Ozempic/Wegovy, Zepbound): boxed warning: contraindicated with personal/family history of MTC or MEN2.", "guideline_quote": "FDA label (Ozempic/Wegovy, Zepbound): boxed warning: contraindicated with personal/family history of MTC or MEN2.", "source_snippet": "Family history of medullary thyroid carcinoma noted", "evidence_field": "Agent evidence", "evidence_raw": "history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'; medication.drug=tirzepatide, is_dose_escalation=true", "evidence_label": "history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'; medication.drug=tirzepatide, is_dose_escalation=true", "why": "Family history of medullary thyroid carcinoma documented while continuing tirzepatide dose escalation", "note": "Encounter SYN-0026\nPatient: Female, 43 · BMI 38.0\nComorbidities: type 2 diabetes, dyslipidemia, NAFLD, OSA\nContraindication history: personal MTC no; family MTC yes; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Zepbound / Mounjaro (tirzepatide), 15.0 mg weekly (escalation after 4 weeks on prior dose)\nLabs: HbA1c 6.5; eGFR 57\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nTitration visit. 43yo F with type 2 diabetes and obesity (BMI 38.0). On Zepbound (tirzepatide) 15.0 mg weekly. Escalating dose; 4 weeks on the prior dose. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Family history of medullary thyroid carcinoma noted. Pregnancy status reviewed; not pregnant, contraception discussed. Labs: HbA1c 6.5%, eGFR 57, ALT 34, TSH 3.09. Reports constipation; counseled on management. Follow-up scheduled in 56 days.\n\nAssessment\nObesity with type 2 diabetes, on GLP-1 therapy.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:08:28.711Z", "independent_summary": "Family history of medullary thyroid carcinoma is documented while tirzepatide dose escalation continues without addressing the boxed-warning contraindication.", "reasoning_trace": [ "Reviewed MTC/MEN2: screening is documented, but family_history_mtc=true with ongoing tirzepatide escalation conflicts with the boxed-warning contraindication.", "Pregnancy status addressed (not pregnant, contraception discussed); no E_MISSING_PREGNANCY_STATUS.", "No pancreatitis history; no concurrent insulin or sulfonylurea; no eating-disorder history—no E_PANCREATITIS_HISTORY, E_INSULIN_INTERACTION, or E_EATING_DISORDER_HISTORY.", "BMI 38, HbA1c 6.5%, and eGFR 57 are present; titration at 4 weeks on prior dose and follow-up in 56 days meet interval/monitoring expectations—no E_MISSING_BMI, E_MISSING_BASELINE_HBA1C, E_MISSING_RENAL, E_RAPID_TITRATION, or follow-up omission flags.", "reference_context [1]–[3] were not used; they address cardiorenal outcomes, not MTC contraindication." ], "reasoning_steps": [ "Observed: Structured history.family_history_mtc=true and note states 'Family history of medullary thyroid carcinoma noted' while plan escalates tirzepatide 15 mg weekly.", "Source: Knowledge card boxed warning—GLP-1/GIP agents are contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN2.", "Gap: Note documents screening and family history but does not address the labeling contraindication, risk-benefit rationale, or alternative therapy before continuing escalation.", "Conclusion: Use of tirzepatide with documented family history of MTC is a director-facing boxed-warning safety concern warranting independent review, not a treatment recommendation." ], "agent_message": "Family history of medullary thyroid carcinoma documented while continuing tirzepatide dose escalation", "agent_evidence": "history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'; medication.drug=tirzepatide, is_dose_escalation=true", "kb_excerpts": [ { "n": 1, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 2, "title": "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. (glp1-tirzepatide §abstract; DOI 10.1001/jamacardio.2026.0767)", "body": "Importance: The dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide was noninferior to a GLP-1 agonist, dulaglutide, for effects on the composite outcome of cardiovascular death, myocardial infarction (MI), or stroke. However, comparison..." }, { "n": 3, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_CONTRAINDICATION_MTC", "severity": "high", "message": "Family history of medullary thyroid carcinoma documented while continuing tirzepatide dose escalation", "evidence": "history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'; medication.drug=tirzepatide, is_dose_escalation=true", "reasoning_steps": [ "Observed: Structured history.family_history_mtc=true and note states 'Family history of medullary thyroid carcinoma noted' while plan escalates tirzepatide 15 mg weekly.", "Source: Knowledge card boxed warning—GLP-1/GIP agents are contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN2.", "Gap: Note documents screening and family history but does not address the labeling contraindication, risk-benefit rationale, or alternative therapy before continuing escalation.", "Conclusion: Use of tirzepatide with documented family history of MTC is a director-facing boxed-warning safety concern warranting independent review, not a treatment recommendation." ] } ], "rules_codes": [ "E_CONTRAINDICATION_MTC" ] }, "liability_pack": { "flag": { "request_id": "SYN-0026", "error_code": "E_CONTRAINDICATION_MTC", "message": "Family history of medullary thyroid carcinoma documented while continuing tirzepatide dose escalation", "evidence": "history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'; medication.drug=tirzepatide, is_dose_escalation=true", "note_excerpt": "Family history of medullary thyroid carcinoma noted", "clinical_brief": "Family history of medullary thyroid carcinoma is documented while tirzepatide dose escalation continues without addressing the boxed-warning contraindication.", "clinical_title": "MTC / MEN2 history on GLP-1", "medication": "Zepbound / Mounjaro (tirzepatide) 15.0 mg weekly" }, "liability": { "request_id": "SYN-0026", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Shows FDA enforcement attention to entities offering tirzepatide and other GLP-1-related products, supplying regulatory-context backdrop for oversight of GLP-1 use—not a finding about this clinic’s MTC screening. Cite [1].", "used_part": "FDA reviewed website content and observed offers of various compounded drug products, including retatrutide, semaglutide and tirzepatide, described as unapproved new drugs and misbranded drugs in interstate commerce.", "citation_tag": "[1]" }, { "item_type": "court_docket", "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (MDL No. 3094)", "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "date": "2023-12-01", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Establishes existence of centralized federal product-liability litigation over GLP-1 RAs, relevant only as public volume/posture context for the drug class implicated by this tirzepatide concern; not clinic malpractice. Cite [4].", "used_part": "Judicial Panel on Multidistrict Litigation materials captioned In re Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, including plaintiffs’ motion for transfer under 28 U.S.C. § 1407.", "citation_tag": "[4]" }, { "item_type": "court_opinion", "title": "In re Incretin-Based Therapies Products Liability Litigation", "url": "https://www.courtlistener.com/opinion/7316647/in-re-incretin-based-therapies-products-liability-litigation/", "date": "2015-11-09", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Prior incretin MDL summary-judgment opinion illustrates that failure-to-warn product claims in this therapeutic area are manufacturer- and label-centric and fact-specific; used to caution against equating public product litigation with this visit’s documentation gap. Cite [6].", "used_part": "Order granting defendants’ motion for summary judgment and denying plaintiffs’ cross-motion for summary judgment in In re Incretin-Based Therapies Products Liability Litigation, discussing the FDCA framework in that litigation.", "citation_tag": "[6]" } ], "executive_summary": "This oversight brief concerns continued tirzepatide dose escalation despite documented family history of medullary thyroid carcinoma, a boxed-warning contraindication theme on the product labeling. Public authorities in the supplied corpus reflect active GLP-1 product-liability multidistrict activity and FDA warning-letter enforcement against certain GLP-1 market participants, but they do not adjudicate clinic-level contraindication screening or documentation for MTC/MEN2. No settlement, verdict, fine, or penalty dollar figures appear in the retrieved records for this concern. The memorandum therefore supplies public-pattern context only and does not assess liability for this visit or clinic. Director-facing review may focus on whether the record addresses the labeled contraindication before escalation.", "director_summary": "This oversight brief concerns continued tirzepatide dose escalation despite documented family history of medullary thyroid carcinoma, a boxed-warning contraindication theme on the product labeling. Public authorities in the supplied corpus reflect active GLP-1 product-liability multidistrict activity and FDA warning-letter enforcement against certain GLP-1 market participants, but they do not adjudicate clinic-level contraindication screening or documentation for MTC/MEN2. No settlement, verdict, fine, or penalty dollar figures appear in the retrieved records for this concern. The memorandum therefore supplies public-pattern context only and does not assess liability for this visit or clinic. Director-facing review may focus on whether the record addresses the labeled contraindication before escalation.", "report": { "matter": "MTC/MEN2 family-history contraindication and ongoing tirzepatide escalation", "scope": "Single-visit clinical concern (family history of medullary thyroid carcinoma with continued tirzepatide dose escalation) plus vetted public authorities only: FDA warning letters and GLP-1/incretin court dockets and opinions in reference_context.", "facts_considered": "Female patient, 43. Structured and narrative documentation reflect family history of medullary thyroid carcinoma (history.family_history_mtc=true; note: 'Family history of medullary thyroid carcinoma noted.'). Medication is tirzepatide (Zepbound/Mounjaro) at 15.0 mg weekly with dose escalation continuing. Supplied reasoning notes that the chart documents the family history but does not record addressing the labeling contraindication, risk-benefit rationale, or alternative therapy before escalation.", "issue_presented": "Whether public-record patterns concerning GLP-1 labeling, warnings, and product-liability litigation supply oversight context when a visit record documents family history of MTC while tirzepatide dose escalation continues without charted engagement of the boxed-warning contraindication.", "analysis": "The clinical concern is process- and documentation-oriented: family history of medullary thyroid carcinoma is noted while tirzepatide escalation to 15 mg weekly proceeds without a recorded response to the labeled MTC/MEN2 contraindication theme. Public materials supplied do not decide clinic malpractice standards for that gap; they frame the broader enforcement and litigation environment around GLP-1 receptor agonists.\n\nFDA warning letters in the corpus address unlawful marketing or quality issues for certain compounded or foreign-manufactured GLP-1-related products, including offerings of tirzepatide among other agents [1], and significant CGMP deviations at a foreign drug manufacturing facility [2]. Those actions illustrate regulatory attention to GLP-1 product quality and promotion; they are not findings about this clinic’s prescribing documentation or this patient’s care.\n\nSeparately, federal multidistrict dockets consolidate numerous product-liability actions involving GLP-1 receptor agonists, including MDL No. 3094 and a streamlined NAION-related docket naming Eli Lilly among parties [3][4]. Those proceedings concern manufacturer product-liability theories, not a determination that any particular clinic failed to honor an MTC/MEN2 contraindication. Earlier incretin-based therapies litigation produced summary-judgment rulings for defendants in pancreatic-cancer failure-to-warn theories under a different factual and regulatory record [5][6]. Those opinions underscore that labeling and preemption disputes in the incretin/GLP-1 space are heavily fact-specific and manufacturer-focused; they do not establish liability, or exonerate liability, for clinic-level continuation of tirzepatide after documented family history of MTC.\n\nTaken together, the public corpus supports heightened oversight sensitivity to boxed-warning and screening documentation when GLP-1 therapy is escalated, while remaining silent on dollar exposure or outcome for this visit.", "observations": [ "[1][2] FDA warning-letter activity in the supplied set targets compounded/offered GLP-1 products (including tirzepatide) and foreign manufacturing CGMP issues, indicating sustained federal enforcement posture in the GLP-1 marketplace rather than clinic chart review.", "[3][4] Public dockets reflect centralized product-liability litigation over GLP-1 receptor agonists (including NAION-related streamlined proceedings and MDL No. 3094), evidencing volume and coordination of manufacturer-focused suits, not adjudicated clinic contraindication failures.", "[5][6] Prior incretin product-liability opinions granted defendants summary judgment on certain failure-to-warn theories, illustrating that warning-label litigation in this drug class turns on specific regulatory and scientific records and is not interchangeable with visit-level MTC/MEN2 documentation concerns." ], "limitations": "This memorandum does not prove that the clinic violated any standard of care, that the boxed-warning contraindication was clinically applicable after full history clarification, or that any patient injury occurred. Public records cited are predominantly manufacturer product-liability dockets/opinions and FDA letters to unrelated entities; they do not describe this clinic, this visit, or any settlement or verdict tied to MTC/MEN2 contraindication screening. Absence of charted contraindication discussion in the supplied excerpt is not itself a public-record finding of negligence.", "director_considerations": "Consider whether the medical record clearly reconciles documented family history of medullary thyroid carcinoma with continued tirzepatide escalation, including any clarification of personal versus family history, MEN2 context if obtained, and the rationale for proceeding or for alternative therapy. Consider a structured contraindication/screening attestation at initiation and at dose-escalation checkpoints for GLP-1/GIP agents. Any peer review should remain documentation- and process-focused; this brief does not direct a clinical or legal course of action.", "risk_band": "moderate" }, "exposure": { "summary": "Retrieved public authorities show active GLP-1 product-liability multidistrict litigation and FDA warning-letter enforcement against certain GLP-1 sellers and manufacturers, which forms qualitative backdrop for oversight of labeled contraindications. No public settlement, verdict, award, fine, or civil-penalty amounts are stated in the supplied reference_context for MTC/MEN2 contraindication issues or for clinic-level care. Manufacturer MDL activity is not a measure of this clinic’s expected loss.", "figures": [], "basis": "Analogical use only of FDA warning letters regarding GLP-1-related products [1][2] and public GLP-1/incretin product-liability dockets and opinions [3][4][5][6]; no clinic-malpractice awards or MTC-specific penalty figures were present.", "confidence": "none", "transparency_note": "No public settlement, verdict, fine, penalty, or other dollar exposure figures appear in the retrieved reference_context. Filing fees are not used as exposure estimates. Nothing in the corpus quantifies financial exposure for this clinic or this visit." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:48.360Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 2, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "body": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation\nCourt: United States Judicial Panel on Multidistrict Litigation\nDocket: MDL No. 3094\nFiled: 2023-12-01\nParties: Liaison Counsel for Plaintiffs; Liaison Counsel for Defendants Filing: Brief — Case MDL No. 3094 Document 1-1 Filed 12/01/23 Page 1 of 21 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLP-1 RECEPTOR AGONIST CASES MDL DOCKET NO.______ MEMORANDUM IN SUPPORT OF PLAINTIFFS’ MOTION FOR TRANSFER OF ACTIONS TO THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA PURSUANT TO 28 U.S.C. § Filing: Response to Motion to Transfer — Case MDL No. 3094 Document 58 Filed 12/29/23 Page 1 of 24 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLUCAGON-LIKE PEPTIDE-1 MDL No. 3094 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATI" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "In re Incretin-Based Therapies Products Liability Litigation", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7316647/in-re-incretin-based-therapies-products-liability-litigation/", "body": "In re Incretin-Based Therapies Products Liability Litigation\nCourt: District Court, S.D. California\nDocket: Case No.: 13md2452 AJB (MDD)\nFiled: 2015-11-09\nCitation: 142 F. Supp. 3d 1108; 2015 U.S. Dist. LEXIS 152763; 2015 WL 6912689\n*1111ORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT AND DENYING PLAINTIFFS’ CROSS-MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION Through the ■ enactment of the Federal Food, Drug, 'and Cosmetics Act, *1112" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0136", "priority": "high", "title": "Pancreatitis history on GLP-1", "full_message": "Prior acute pancreatitis documented; continuing semaglutide without explicit risk justification", "patient_label": "Male, 32", "visit_date": "2026-07-12", "medication": "Wegovy / Ozempic (semaglutide) 1.0 mg weekly", "flag_code": "E_PANCREATITIS_HISTORY", "rule_id": "R02", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label: Warnings/Precautions: history of pancreatitis requires risk consideration.", "guideline_quote": "FDA label: Warnings/Precautions: history of pancreatitis requires risk consideration.", "source_snippet": "History of acute pancreatitis", "evidence_field": "Agent evidence", "evidence_raw": "history.history_pancreatitis=true; doctor_report.note_text: 'History of acute pancreatitis'; doctor_report.plan: 'Continue per titration schedule. Labs reviewed. Follow-up scheduled.'", "evidence_label": "history.history_pancreatitis=true; doctor_report.note_text: 'History of acute pancreatitis'; doctor_report.plan: 'Continue per titration schedule. Labs reviewed. Follow-up scheduled.'", "why": "Prior acute pancreatitis documented; continuing semaglutide without explicit risk justification", "note": "Encounter SYN-0136\nPatient: Male, 32 · BMI 47.1\nComorbidities: type 2 diabetes, NAFLD\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis yes; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: Wegovy / Ozempic (semaglutide), 1.0 mg weekly\nLabs: HbA1c 8.9; eGFR 72\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nFollow-up visit. 32yo M with type 2 diabetes and obesity (BMI 47.1). On Wegovy (semaglutide) 1.0 mg weekly. Screened for personal/family history of medullary thyroid carcinoma and MEN2. History of acute pancreatitis. Labs: HbA1c 8.9%, eGFR 72, ALT 24, TSH 2.66. No new GI symptoms reported. Follow-up scheduled in 28 days.\n\nAssessment\nObesity with type 2 diabetes, on GLP-1 therapy.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:08:42.775Z", "independent_summary": "Prior acute pancreatitis is acknowledged, but the plan to continue semaglutide lacks explicit risk justification.", "reasoning_trace": [ "Confirmed MTC/MEN2 screening documented in note with structured personal_history_mtc=false, family_history_mtc=false, men2=false — no E_CONTRAINDICATION_MTC or E_NO_MEN2_SCREEN.", "Patient is 32yo male; pregnancy status not applicable — no E_MISSING_PREGNANCY_STATUS.", "BMI 47.1, HbA1c 8.9%, and eGFR 72 are present; follow-up scheduled in 28 days — no baseline-lab or follow-up omission flags.", "Not a new start or dose escalation (weeks_on_current_dose=8, is_dose_escalation=false); no insulin/sulfonylurea, eating disorder, or compounded product — no E_RAPID_TITRATION, E_INSULIN_INTERACTION, E_EATING_DISORDER_HISTORY, or E_COMPOUNDED_NO_DISCLOSURE.", "Prior pancreatitis is documented in structured history and note, but plan only continues titration without explicit pancreatitis risk justification — flagged E_PANCREATITIS_HISTORY.", "reference_context [1]-[3] reviewed; none cited in evidence because excerpts do not address pancreatitis risk." ], "reasoning_steps": [ "Observed: Structured history flags history_pancreatitis=true and the note states 'History of acute pancreatitis' while continuing Wegovy (semaglutide) 1.0 mg weekly.", "Source: Knowledge card — caution with a history of pancreatitis requires explicit risk justification; reference_context [1]-[3] does not address pancreatitis and was not used.", "Gap: Assessment and plan do not document risk-benefit rationale, pancreatitis monitoring, or stop/restart criteria despite acknowledged prior pancreatitis.", "Conclusion: Continuing GLP-1 therapy with documented pancreatitis history but no explicit justification is a director-facing safety documentation concern, not a treatment directive." ], "agent_message": "Prior acute pancreatitis documented; continuing semaglutide without explicit risk justification", "agent_evidence": "history.history_pancreatitis=true; doctor_report.note_text: 'History of acute pancreatitis'; doctor_report.plan: 'Continue per titration schedule. Labs reviewed. Follow-up scheduled.'", "kb_excerpts": [ { "n": 1, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 2, "title": "Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. (glp1-semaglutide §abstract; DOI 10.3389/fmed.2026.1764664)", "body": "Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an effective therapy for obesity and type 2 diabetes mellitus (T2DM). Its dual-incretin mechanism may offer enhanced metabolic benefits compared..." }, { "n": 3, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_PANCREATITIS_HISTORY", "severity": "high", "message": "Prior acute pancreatitis documented; continuing semaglutide without explicit risk justification", "evidence": "history.history_pancreatitis=true; doctor_report.note_text: 'History of acute pancreatitis'; doctor_report.plan: 'Continue per titration schedule. Labs reviewed. Follow-up scheduled.'", "reasoning_steps": [ "Observed: Structured history flags history_pancreatitis=true and the note states 'History of acute pancreatitis' while continuing Wegovy (semaglutide) 1.0 mg weekly.", "Source: Knowledge card — caution with a history of pancreatitis requires explicit risk justification; reference_context [1]-[3] does not address pancreatitis and was not used.", "Gap: Assessment and plan do not document risk-benefit rationale, pancreatitis monitoring, or stop/restart criteria despite acknowledged prior pancreatitis.", "Conclusion: Continuing GLP-1 therapy with documented pancreatitis history but no explicit justification is a director-facing safety documentation concern, not a treatment directive." ] } ], "rules_codes": [ "E_PANCREATITIS_HISTORY" ] }, "liability_pack": { "flag": { "request_id": "SYN-0136", "error_code": "E_PANCREATITIS_HISTORY", "message": "Prior acute pancreatitis documented; continuing semaglutide without explicit risk justification", "evidence": "history.history_pancreatitis=true; doctor_report.note_text: 'History of acute pancreatitis'; doctor_report.plan: 'Continue per titration schedule. Labs reviewed. Follow-up scheduled.'", "note_excerpt": "History of acute pancreatitis", "clinical_brief": "Prior acute pancreatitis is acknowledged, but the plan to continue semaglutide lacks explicit risk justification.", "clinical_title": "Pancreatitis history on GLP-1", "medication": "Wegovy / Ozempic (semaglutide) 1.0 mg weekly" }, "liability": { "request_id": "SYN-0136", "related": [ { "item_type": "court_docket", "title": "IN RE: GLP-1 RAs Products Liability Litigation (MDL No. 3094)", "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "date": "2023-12-01", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Shows consolidated manufacturer-facing GLP-1 product-liability activity as qualitative public context only; not a clinic-malpractice authority for pancreatitis documentation on this visit [4].", "used_part": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094; memorandum in support of plaintiffs’ motion for transfer under 28 U.S.C. § 1407.", "citation_tag": "[4]" }, { "item_type": "court_opinion", "title": "Seufert v. Merck Sharp & Dohme Corp.", "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "date": "2016-05-11", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Illustrates historical product-liability litigation involving incretin therapies and pancreatic-risk theories; supplied passage does not set clinic documentation duties for prior pancreatitis [5].", "used_part": "Order granting defendants’ motion for summary judgment; introductory reference to FDA publication in the New England Journal of Medicine regarding large diabetic patient populations.", "citation_tag": "[5]" }, { "item_type": "warning_letter", "title": "GLP-1 Solution — FDA Warning Letter 715883", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Confirms FDA enforcement posture toward certain GLP-1-related compounded/unapproved offerings; not applicable to branded Wegovy/Ozempic pancreatitis-history charting in this concern [2].", "used_part": "FDA reviewed website content offering compounded drug products including retatrutide, semaglutide and tirzepatide; retatrutide products described as unapproved new drugs and misbranded drugs.", "citation_tag": "[2]" } ], "executive_summary": "This oversight brief concerns continued semaglutide (Wegovy/Ozempic) at 1.0 mg weekly where the record acknowledges prior acute pancreatitis but the plan lacks explicit risk-benefit justification, monitoring parameters, or stop criteria. The supplied public corpus contains GLP-1 manufacturer product-liability docket activity and unrelated FDA warning letters; it does not supply clinic-malpractice opinions or enforcement actions on pancreatitis-history documentation. No public settlement, verdict, or fine amounts in the retrieved materials attach to this documentation theme. Public-record signal for director oversight is therefore limited to general GLP-1 litigation context and is insufficient to characterize visit-level liability.", "director_summary": "This oversight brief concerns continued semaglutide (Wegovy/Ozempic) at 1.0 mg weekly where the record acknowledges prior acute pancreatitis but the plan lacks explicit risk-benefit justification, monitoring parameters, or stop criteria. The supplied public corpus contains GLP-1 manufacturer product-liability docket activity and unrelated FDA warning letters; it does not supply clinic-malpractice opinions or enforcement actions on pancreatitis-history documentation. No public settlement, verdict, or fine amounts in the retrieved materials attach to this documentation theme. Public-record signal for director oversight is therefore limited to general GLP-1 litigation context and is insufficient to characterize visit-level liability.", "report": { "matter": "Pancreatitis history — continued semaglutide without documented risk justification", "scope": "Single-visit clinical concern (pancreatitis history with continued semaglutide) plus vetted public authorities in reference_context only: FDA warning letters, GLP-1 MDL/docket materials, and selected court opinions.", "facts_considered": "Structured history flags history of pancreatitis; note excerpt states 'History of acute pancreatitis.' Medication is Wegovy/Ozempic (semaglutide) 1.0 mg weekly. Plan states continue per titration schedule, labs reviewed, follow-up scheduled. Assessment and plan as supplied do not document explicit risk-benefit rationale, pancreatitis-specific monitoring, or stop/restart criteria. Patient labeled male, 32.", "issue_presented": "Whether continuation of a GLP-1 agonist after acknowledged prior acute pancreatitis, without explicit documented risk justification or related safety parameters, presents a process and documentation oversight concern under public-record patterns.", "analysis": "The clinical concern is narrow and documentation-centered: prior acute pancreatitis is recorded, yet the plan continues semaglutide on a standard titration path without an articulated risk-benefit discussion or pancreatitis-focused follow-up criteria in the supplied note. Public authorities retrieved for this brief do not map cleanly onto that clinic-level process issue.\n\nReference materials include FDA warning letters directed at offshore manufacturing deviations and at a foreign website offering compounded GLP-1-related products [1][2]. Those letters address CGMP and unapproved/misbranded drug distribution, not prescriber documentation of pancreatitis history for branded semaglutide. Multidistrict product-liability activity concerning GLP-1 receptor agonists reflects aggregated manufacturer-facing litigation themes, including a dedicated MDL and a streamlined NAION docket [3][4]. Manufacturer product-liability aggregation is not equivalent to a clinic malpractice determination and does not prescribe charting standards for pancreatitis history.\n\nAn older district-court summary-judgment opinion in incretin-related pancreatic injury litigation illustrates that pancreatic risk theories have been litigated in the product-liability setting, but the supplied excerpt does not establish duties owed by a treating clinic or documentation rules for continuing therapy after prior pancreatitis [5]. A state appellate matter involving a health-care authority is not on point for this visit concern [6]. Accordingly, public records support only a general awareness that GLP-1 therapies attract regulatory and product-liability attention; they do not demonstrate breach, causation, or liability as to this visit.", "observations": [ "[1] Public FDA warning letters in the corpus target manufacturing quality and compounded/unapproved GLP-1-related marketing, not clinic documentation of pancreatitis history when continuing branded semaglutide.", "[2] GLP-1 receptor agonist product-liability MDL and related docket activity indicate sustained manufacturer-facing litigation volume, which is a qualitative backdrop distinct from medical-negligence claims against a treating clinic [3][4].", "[3] Retrieved opinions and dockets do not state public settlement, verdict, or civil-penalty figures tied to failure to document risk justification after pancreatitis history, and do not articulate a clinic charting standard for that scenario [5][6]." ], "limitations": "This memorandum does not prove that the clinic departed from the standard of care, that continuing semaglutide was clinically inappropriate, or that any claim has been or will be asserted. It does not evaluate the full medical record, informed-consent discussions outside the excerpt, labeling relied upon at the visit, or patient-specific contraindications beyond the supplied flags. Public dockets and letters cited are not findings about this clinic, this prescriber, or this patient.", "director_considerations": "For oversight quality review, consider whether the chart should reflect acknowledgment of prior acute pancreatitis alongside a concise risk-benefit rationale for continuation or deprescribing, any symptoms or labs weighed, patient counseling noted, and clear return precautions or hold parameters. Any review should remain documentation- and process-focused and is not a treatment directive.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials reflect manufacturer-oriented GLP-1 product-liability docket consolidation and unrelated FDA warning-letter activity. They do not state settlement, verdict, fine, or penalty dollar amounts applicable to clinic documentation of pancreatitis history. No public figure in the corpus should be read as this clinic’s expected loss on this visit.", "figures": [], "basis": "Analogy limited to presence of GLP-1 MDL/docket activity [3][4] and non-analogous FDA warning letters [1][2]; Seufert opinion excerpt addresses incretin-related product litigation context without clinic-documentation holdings or dollars [5]. No grounded monetary exposure figures.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, award, fine, or civil-penalty amounts for pancreatitis-history documentation or clinic continuation of semaglutide. No dollar figures are available to report." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:52.090Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "body": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation\nCourt: United States Judicial Panel on Multidistrict Litigation\nDocket: MDL No. 3094\nFiled: 2023-12-01\nParties: Liaison Counsel for Plaintiffs; Liaison Counsel for Defendants Filing: Brief — Case MDL No. 3094 Document 1-1 Filed 12/01/23 Page 1 of 21 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLP-1 RECEPTOR AGONIST CASES MDL DOCKET NO.______ MEMORANDUM IN SUPPORT OF PLAINTIFFS’ MOTION FOR TRANSFER OF ACTIONS TO THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA PURSUANT TO 28 U.S.C. § Filing: Response to Motion to Transfer — Case MDL No. 3094 Document 58 Filed 12/29/23 Page 1 of 24 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLUCAGON-LIKE PEPTIDE-1 MDL No. 3094 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATI" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Jeannette Simonton, V. Washington State Health Care Authority", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10852801/jeannette-simonton-v-washington-state-health-care-authority/", "body": "Jeannette Simonton, V. Washington State Health Care Authority\nCourt: Court of Appeals of Washington\nDocket: 86988-4\nFiled: 2026-05-04\nIN THE COURT OF APPEALS OF THE STATE OF WASHINGTON JEANNETTE SIMONTON and RYAN KELSO, each on their own behalf and No. 86988-4-I on behalf of similarly situated others, DIVISION ONE Appellants, PUBLISHED OPINION v. WASHINGTON STATE HEALTH CARE AUTHORITY; and SUE BIRCH, director of the Washington State Health Care Authority and chair of t" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0001", "priority": "medium", "title": "No follow-up scheduled", "full_message": "Ongoing GLP-1 titration with active vomiting; no follow-up visit scheduled", "patient_label": "Female, 47", "visit_date": "2026-07-11", "medication": "Wegovy / Ozempic (semaglutide) 0.5 mg weekly", "flag_code": "E_NO_FOLLOWUP_PLAN", "rule_id": "R09", "rulebook": "clinic_protocol", "rulebook_label": "Clinic protocol", "source_cite": "Chronic-therapy continuity-of-care standard.", "guideline_quote": "Chronic-therapy continuity-of-care standard.", "source_snippet": "Follow-up visit: not scheduled.", "evidence_field": "Agent evidence", "evidence_raw": "visit.follow_up_scheduled=false; visit.follow_up_interval_days=null; note: 'No follow-up visit scheduled at this time.' (plan field states 'Follow-up scheduled.' — contradicts note/structured fields)", "evidence_label": "visit.follow_up_scheduled=false; visit.follow_up_interval_days=null; note: 'No follow-up visit scheduled at this time.' (plan field states 'Follow-up scheduled.' — contradicts note/structured fields)", "why": "Ongoing GLP-1 titration with active vomiting; no follow-up visit scheduled", "note": "Encounter SYN-0001\nPatient: Female, 47 · BMI 43.8\nComorbidities: NAFLD, OSA\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Wegovy / Ozempic (semaglutide), 0.5 mg weekly\nLabs: HbA1c 5.8; eGFR 114\nFollow-up scheduled: no\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nFollow-up visit. 47yo F on GLP-1 for weight management, BMI 43.8. On Wegovy (semaglutide) 0.5 mg weekly. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Pregnancy status reviewed; not pregnant, contraception discussed. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 5.8%, eGFR 114, ALT 28, TSH 1.9. Reports vomiting; counseled on management. No follow-up visit scheduled at this time.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:09:58.833Z", "independent_summary": "Chart is largely protocol-concordant, but no follow-up visit is documented despite ongoing titration and vomiting.", "reasoning_trace": [ "Reviewed MTC/MEN2 screening, pregnancy status, and pancreatitis history — all addressed in note and structured fields; no E_CONTRAINDICATION_MTC, E_NO_MEN2_SCREEN, E_MISSING_PREGNANCY_STATUS, or E_PANCREATITIS_HISTORY flags.", "Confirmed eligibility and baseline data: BMI 43.8, HbA1c 5.8%, eGFR 114 present; prior weight-loss attempts documented; not a new start — no E_BMI_BELOW_THRESHOLD, E_MISSING_BMI, E_MISSING_BASELINE_HBA1C, E_MISSING_RENAL, E_MISSING_PRIOR_ATTEMPTS, or E_NO_CONSENT flags.", "No concurrent insulin or sulfonylurea, no compounded formulation, no eating-disorder history, and not a dose-escalation visit at 4 weeks on 0.5 mg — no E_INSULIN_INTERACTION, E_COMPOUNDED_NO_DISCLOSURE, E_EATING_DISORDER_HISTORY, or E_RAPID_TITRATION flags.", "Follow-up review: is_dose_escalation=false so E_DOSE_ESCALATION_NO_FOLLOWUP not applied; however structured fields and primary note confirm no scheduled follow-up despite plan to continue titration with vomiting — flagged E_NO_FOLLOWUP_PLAN.", "reference_context excerpts [1]–[3] were not needed for any flag; monitoring expectation drawn from the knowledge card." ], "reasoning_steps": [ "Observed: Structured visit fields show follow_up_scheduled=false and follow_up_interval_days=null; note_text explicitly states no follow-up visit scheduled, while plan text contradicts this.", "Source: Knowledge card — monitoring/follow-up is expected, especially around dose changes.", "Gap: Patient continues semaglutide per titration schedule with reported vomiting, but no follow-up interval or scheduled visit is documented in structured fields or the primary note.", "Conclusion: A medical director should confirm whether appropriate monitoring and follow-up are arranged for ongoing GLP-1 therapy with an active GI adverse event." ], "agent_message": "Ongoing GLP-1 titration with active vomiting; no follow-up visit scheduled", "agent_evidence": "visit.follow_up_scheduled=false; visit.follow_up_interval_days=null; note: 'No follow-up visit scheduled at this time.' (plan field states 'Follow-up scheduled.' — contradicts note/structured fields)", "kb_excerpts": [ { "n": 1, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 2, "title": "A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. (glp1-semaglutide §abstract; DOI 10.7759/cureus.107970)", "body": "Obesity is an increasingly growing public health issue affecting a substantial proportion of the population in the United States. This condition increases the risk for multiple disease processes, including cardiometabolic disorders, osteoarthritis, gout, respiratory issues, reproductive problems,..." }, { "n": 3, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_NO_FOLLOWUP_PLAN", "severity": "medium", "message": "Ongoing GLP-1 titration with active vomiting; no follow-up visit scheduled", "evidence": "visit.follow_up_scheduled=false; visit.follow_up_interval_days=null; note: 'No follow-up visit scheduled at this time.' (plan field states 'Follow-up scheduled.' — contradicts note/structured fields)", "reasoning_steps": [ "Observed: Structured visit fields show follow_up_scheduled=false and follow_up_interval_days=null; note_text explicitly states no follow-up visit scheduled, while plan text contradicts this.", "Source: Knowledge card — monitoring/follow-up is expected, especially around dose changes.", "Gap: Patient continues semaglutide per titration schedule with reported vomiting, but no follow-up interval or scheduled visit is documented in structured fields or the primary note.", "Conclusion: A medical director should confirm whether appropriate monitoring and follow-up are arranged for ongoing GLP-1 therapy with an active GI adverse event." ] } ], "rules_codes": [ "E_NO_FOLLOWUP_PLAN" ] }, "liability_pack": { "flag": { "request_id": "SYN-0001", "error_code": "E_NO_FOLLOWUP_PLAN", "message": "Ongoing GLP-1 titration with active vomiting; no follow-up visit scheduled", "evidence": "visit.follow_up_scheduled=false; visit.follow_up_interval_days=null; note: 'No follow-up visit scheduled at this time.' (plan field states 'Follow-up scheduled.' — contradicts note/structured fields)", "note_excerpt": "Follow-up visit: not scheduled.", "clinical_brief": "Chart is largely protocol-concordant, but no follow-up visit is documented despite ongoing titration and vomiting.", "clinical_title": "No follow-up scheduled", "medication": "Wegovy / Ozempic (semaglutide) 0.5 mg weekly" }, "liability": { "request_id": "SYN-0001", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution FDA Warning Letter", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Shows FDA enforcement posture toward GLP-1-related drug offerings; used only as ambient regulatory context, not as a standard for clinic follow-up documentation on this visit [2].", "used_part": "FDA reviewed website content and observed offers of various compounded drug products, including retatrutide, semaglutide and tirzepatide, described as unapproved new drugs and misbranded drugs.", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation (E.D. Pa.)", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Documents MDL transfer activity for GLP-1 RA product-liability claims; cited solely to note manufacturer-side litigation context, which is distinct from clinic follow-up-plan documentation [3].", "used_part": "Transfer order from the Judicial Panel on Multidistrict Litigation consolidating GLP-1 RAs non-arteritic anterior ischemic optic neuropathy products liability actions in the Eastern District of Pennsylvania.", "citation_tag": "[3]" }, { "item_type": "court_docket", "title": "Bjorklund v. Novo Nordisk A/S", "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "date": "2024-02-05", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_MALPRACTICE_NEGLIGENCE" ], "relevance": "Example personal-injury / product-liability docket naming Novo Nordisk entities in the GLP-1 space; used only to illustrate the existence of manufacturer-directed suits, not liability for this clinic’s follow-up entry [4].", "used_part": "Docket reflects diversity personal-injury product-liability action with parties including Novo Nordisk entities and related motion-to-dismiss practice.", "citation_tag": "[4]" } ], "executive_summary": "This oversight brief concerns a documented gap in follow-up planning for a 47-year-old female on ongoing semaglutide titration with active vomiting. Structured visit fields and the primary note state that no follow-up visit was scheduled, while the plan field inconsistently asserts that follow-up was scheduled. Public authorities in the supplied corpus address GLP-1 manufacturing, compounding, and manufacturer product-liability dockets rather than clinic-level follow-up or monitoring standards. No public settlement, verdict, or fine amounts applicable to this visit concern appear in the retrieved records. On a public-record basis alone, the liability signal for this specific documentation gap is insufficient.", "director_summary": "This oversight brief concerns a documented gap in follow-up planning for a 47-year-old female on ongoing semaglutide titration with active vomiting. Structured visit fields and the primary note state that no follow-up visit was scheduled, while the plan field inconsistently asserts that follow-up was scheduled. Public authorities in the supplied corpus address GLP-1 manufacturing, compounding, and manufacturer product-liability dockets rather than clinic-level follow-up or monitoring standards. No public settlement, verdict, or fine amounts applicable to this visit concern appear in the retrieved records. On a public-record basis alone, the liability signal for this specific documentation gap is insufficient.", "report": { "matter": "Missing follow-up plan — GLP-1 titration with active vomiting", "scope": "Review limited to this visit’s clinical concern (missing follow-up plan during semaglutide titration with reported vomiting) and the vetted public reference_context items only (FDA warning letters and court dockets/opinions). No clinic file, deposition, policy manual, or external research was reviewed.", "facts_considered": "Female patient, age 47, on Wegovy/Ozempic (semaglutide) 0.5 mg weekly. Chart described as largely protocol-concordant. Ongoing titration with active vomiting. Structured fields: visit.follow_up_scheduled=false; visit.follow_up_interval_days=null. Note excerpt: “Follow-up visit: not scheduled.” Plan field states “Follow-up scheduled,” which contradicts the note and structured fields. Evidence string records the same contradiction.", "issue_presented": "Whether, for oversight purposes, the absence of a documented follow-up interval or scheduled visit during ongoing GLP-1 titration with an active gastrointestinal adverse event presents a process and documentation vulnerability under public-record patterns bearing on monitoring, continuity, and adverse-event management.", "analysis": "The supplied clinical materials identify a concrete process gap: continued semaglutide titration with reported vomiting and no scheduled follow-up in structured fields or the primary note, alongside an internal inconsistency in the plan field. Public authorities retrieved for this brief do not articulate a clinic standard of care for post-titration follow-up intervals or GI-symptom re-evaluation. FDA warning letters in the corpus address offshore manufacturing CGMP deviations and online offering of unapproved or misbranded compounded GLP-1-related products, not ambulatory follow-up documentation by a prescribing clinic [1][2].\n\nCourt materials likewise center on manufacturer-side product-liability aggregation and related personal-injury pleadings concerning GLP-1 receptor agonists, including multidistrict transfer activity directed at non-arteritic anterior ischemic optic neuropathy claims, rather than negligence theories premised on a missing follow-up plan at a clinic visit [3][4]. An older summary-judgment opinion involving a different manufacturer and different diabetes-drug labeling issues does not supply a holding on follow-up scheduling for semaglutide adverse events [5]. An insurer coverage appeal is not on point for visit-level monitoring documentation [6].\n\nAccordingly, while public dockets reflect an active GLP-1 litigation environment at the product-liability level, those records do not map cleanly onto the documentation and continuity concern presented here. Manufacturer product-liability MDLs are not equivalent to clinic malpractice theories. Any oversight inference must remain limited to the internal inconsistency and the absence of a documented follow-up plan in the face of ongoing titration and vomiting, without treating the cited public matters as proof of breach or causation for this visit.", "observations": [ "[1] Public FDA warning letters in the corpus targeting GLP-1-related products focus on manufacturing quality and unapproved/misbranded compounded offerings, illustrating regulatory enforcement attention to the GLP-1 marketplace rather than clinic follow-up protocols.", "[2] Public docket activity reflects multidistrict product-liability aggregation involving GLP-1 receptor agonists, indicating sustained manufacturer-directed litigation volume; that pattern is not a finding about this clinic’s follow-up practices.", "[3] No supplied public opinion or docket sets out a holding that failure to document a follow-up visit during semaglutide titration with vomiting constitutes actionable negligence by a treating clinic." ], "limitations": "This memorandum does not prove that the clinic breached any duty, that the patient was harmed by the missing follow-up entry, or that any claim has been or will be asserted. It does not resolve the plan-versus-note contradiction with extrinsic evidence. Public records cited do not establish clinic policies, actual monitoring arrangements outside the chart snippet, informed-consent content, or causation. Manufacturer and compounding enforcement matters are not findings about this visit or this provider.", "director_considerations": "Consider reconciling the contradictory plan-field language with structured follow-up fields and the primary note so the record consistently reflects whether, when, and for what clinical purpose follow-up was arranged during ongoing titration with active vomiting. Consider a documentation review focused on how GI adverse events and dose-escalation monitoring are captured in the plan and scheduling modules. This is not legal advice and is not a treatment recommendation.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials reflect manufacturer-directed GLP-1 product-liability docket activity and FDA enforcement against certain manufacturers and online compounders. They do not state settlement, verdict, award, or civil-penalty dollar figures tied to clinic-level failure to schedule follow-up. No public dollar exposure figure is available for this visit concern from the supplied corpus.", "figures": [], "basis": "Qualitative analogy only to GLP-1-related FDA warning letters and manufacturer product-liability dockets in reference_context; no clinic-malpractice damages records or stated dollar amounts were provided.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, fine, or civil-penalty amounts applicable to missing follow-up planning at a clinic visit. No dollar figures are grounded for this concern; figures remain empty." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:56.559Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "Bjorklund v. Novo Nordisk A/S", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "body": "Bjorklund v. Novo Nordisk A/S\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:24-cv-00533\nFiled: 2024-02-05\nCause: 28:1332 Diversity-Personal Injury Parties: ELI LILLY & CO; NOVO NORDISK A/S; Novo Nordisk U S Commercial Holdings Inc; Jaclyn Bjorklund; NOVO NORDISK INC.; NOVO NORDISK RESEARCH CENTER SEATTLE INC.; Novo Nordisk U S Holdings Inc; NOVO NORDISK NORTH AMERICA OPERATIONS A/S; Novo Nordisk Pharmaceutical Industries L P Filing: MEMORANDUM in Opposition re 73 MOTION to Dismiss for Lack of Jurisdiction or in the Alternative to Dismiss Plaintiff's Express Warranty Claim Pursuant to Rule 12(b)(6) MOTION to Dismiss For Failure to State a Claim filed by Jaclyn Bjorklund. (Attachments: # 1 Exhibit Exhibit List, # 2 Exhibit 1- Plaintiffs Declaration, # 3 Exhibit 2- Novo Nordisk A/S Company Profile, Bloomberg, # 4 Exhibit 3- Novo Nordisk A/S, 2022 Annual Report, # 5 Exhibit 4- Novo List" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Holland v. Elevance Health, Inc.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10827843/holland-v-elevance-health-inc/", "body": "Holland v. Elevance Health, Inc.\nCourt: Court of Appeals for the First Circuit\nDocket: 25-1359\nFiled: 2026-03-27\nUnited States Court of Appeals For the First Circuit No. 25-1359 REBECCA HOLLAND, on her own behalf and on behalf of those similarly situated, Plaintiff, Appellant, v. ELEVANCE HEALTH, INC., f/k/a Anthem, Inc., Defendant, Appellee. APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MAINE" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0004", "priority": "medium", "title": "Dose escalated faster than label", "full_message": "Dose escalated after only 1 week on prior dose; faster than ~4-week step interval", "patient_label": "Male, 41", "visit_date": "2026-07-07", "medication": "Zepbound / Mounjaro (tirzepatide) 7.5 mg weekly", "flag_code": "E_RAPID_TITRATION", "rule_id": "R04", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label: Dosage & Administration: dose-escalation interval (minimum ~4 weeks per step).", "guideline_quote": "FDA label: Dosage & Administration: dose-escalation interval (minimum ~4 weeks per step).", "source_snippet": "Escalating dose; 1 week on the prior dose", "evidence_field": "Agent evidence", "evidence_raw": "medication.is_dose_escalation=true; medication.weeks_on_current_dose=1; note: 'Escalating dose; 1 week on the prior dose.'", "evidence_label": "medication.is_dose_escalation=true; medication.weeks_on_current_dose=1; note: 'Escalating dose; 1 week on the prior dose.'", "why": "Dose escalated after only 1 week on prior dose; faster than ~4-week step interval", "note": "Encounter SYN-0004\nPatient: Male, 41 · BMI 41.0\nComorbidities: NAFLD, OSA\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: Zepbound / Mounjaro (tirzepatide), 7.5 mg weekly (escalation after 1 weeks on prior dose)\nLabs: HbA1c 6.1; eGFR 80\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nTitration visit. 41yo M on GLP-1 for weight management, BMI 41.0. On Zepbound (tirzepatide) 7.5 mg weekly. Escalating dose; 1 week on the prior dose. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Labs: HbA1c 6.1%, eGFR 80, ALT 44, TSH 3.23. No new GI symptoms reported. Follow-up scheduled in 42 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:09:05.464Z", "independent_summary": "Dose was escalated after only one week on the prior tirzepatide dose, below the recommended ~4-week titration interval.", "reasoning_trace": [ "Reviewed titration visit: male patient, BMI 41 with NAFLD/OSA; tirzepatide dose escalation to 7.5 mg with labs (HbA1c 6.1%, eGFR 80) and follow-up in 42 days documented.", "MTC/MEN2: note and structured history confirm screening with negative personal/family MTC and no MEN2 — E_CONTRAINDICATION_MTC and E_NO_MEN2_SCREEN not flagged.", "Pregnancy status not applicable (sex=M); pancreatitis history negative; no insulin/sulfonylurea — E_MISSING_PREGNANCY_STATUS, E_PANCREATITIS_HISTORY, and E_INSULIN_INTERACTION not flagged.", "BMI, HbA1c, and eGFR present; follow-up scheduled after escalation — E_MISSING_BMI, E_MISSING_BASELINE_HBA1C, E_MISSING_RENAL, E_DOSE_ESCALATION_NO_FOLLOWUP, and E_NO_FOLLOWUP_PLAN not flagged.", "Flagged E_RAPID_TITRATION based on 1-week interval before escalation (knowledge card); reference_context excerpts [1]-[3] cover indications/general safety but not titration intervals and were not cited.", "No evidence for eating disorder history, compounded product, missing consent on this ongoing therapy visit, or BMI eligibility concerns — those codes not flagged." ], "reasoning_steps": [ "Observed: Titration visit with dose escalation to 7.5 mg; structured field weeks_on_current_dose=1 and note documents only 1 week on the prior dose before escalating.", "Source: GLP-1 knowledge card — titration should escalate no faster than ~4 weeks per dose step; faster escalation raises GI adverse events.", "Gap: Chart documents escalation after 1 week without justification for accelerated titration or mitigation plan for increased GI risk.", "Conclusion: Interval is materially shorter than recommended titration pacing; director review warranted for safety/documentation concordance, not as a treatment directive." ], "agent_message": "Dose escalated after only 1 week on prior dose; faster than ~4-week step interval", "agent_evidence": "medication.is_dose_escalation=true; medication.weeks_on_current_dose=1; note: 'Escalating dose; 1 week on the prior dose.'", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." }, { "n": 3, "title": "FDA label (tirzepatide) - Indications And Usage [part 2] (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_RAPID_TITRATION", "severity": "medium", "message": "Dose escalated after only 1 week on prior dose; faster than ~4-week step interval", "evidence": "medication.is_dose_escalation=true; medication.weeks_on_current_dose=1; note: 'Escalating dose; 1 week on the prior dose.'", "reasoning_steps": [ "Observed: Titration visit with dose escalation to 7.5 mg; structured field weeks_on_current_dose=1 and note documents only 1 week on the prior dose before escalating.", "Source: GLP-1 knowledge card — titration should escalate no faster than ~4 weeks per dose step; faster escalation raises GI adverse events.", "Gap: Chart documents escalation after 1 week without justification for accelerated titration or mitigation plan for increased GI risk.", "Conclusion: Interval is materially shorter than recommended titration pacing; director review warranted for safety/documentation concordance, not as a treatment directive." ] } ], "rules_codes": [ "E_RAPID_TITRATION", "E_MISSING_PRIOR_ATTEMPTS" ] }, "liability_pack": { "flag": { "request_id": "SYN-0004", "error_code": "E_RAPID_TITRATION", "message": "Dose escalated after only 1 week on prior dose; faster than ~4-week step interval", "evidence": "medication.is_dose_escalation=true; medication.weeks_on_current_dose=1; note: 'Escalating dose; 1 week on the prior dose.'", "note_excerpt": "Escalating dose; 1 week on the prior dose", "clinical_brief": "Dose was escalated after only one week on the prior tirzepatide dose, below the recommended ~4-week titration interval.", "clinical_title": "Dose escalated faster than label", "medication": "Zepbound / Mounjaro (tirzepatide) 7.5 mg weekly" }, "liability": { "request_id": "SYN-0004", "related": [ { "item_type": "court_docket", "title": "IN RE: GLP-1 RAs Products Liability Litigation (MDL 3094)", "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "date": "2023-12-01", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Establishes that federal multidistrict products-liability proceedings exist for GLP-1 receptor agonists, supplying class-level litigation context only; not a standard-of-care ruling on one-week titration in this visit [3].", "used_part": "MDL No. 3094 caption and plaintiffs’ transfer memorandum materials regarding GLP-1 receptor agonist products-liability actions before the Judicial Panel on Multidistrict Litigation.", "citation_tag": "[3]" }, { "item_type": "warning_letter", "title": "GLP-1 Solution — FDA Warning Letter 715883", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Shows FDA enforcement attention to tirzepatide and other GLP-1-related products offered online as compounded/unapproved drugs; relevant only as regulatory backdrop for tirzepatide product scrutiny, not as authority on labeled dose-step timing [2].", "used_part": "FDA reviewed website content offering compounded drug products including retatrutide, semaglutide and tirzepatide; retatrutide products described as unapproved new drugs and misbranded drugs in interstate commerce.", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation v. Eli Lilly", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Illustrates additional aggregated products-liability activity involving GLP-1 agents and a manufacturer defendant; used solely to note expanded public litigation posture, not clinic titration liability [4].", "used_part": "Transfer order and caption for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation streamlined docket.", "citation_tag": "[4]" } ], "executive_summary": "This oversight brief concerns a documented tirzepatide dose escalation after only one week on the prior dose, materially shorter than the commonly referenced multi-week step interval. Public authorities in the supplied corpus address GLP-1 manufacturing, compounding, and manufacturer products-liability aggregation, not clinic-level titration pacing. No retrieved record states a settlement, verdict, fine, or penalty amount applicable to accelerated titration in ambulatory care. The public signal is therefore contextual to the GLP-1 litigation and enforcement environment rather than proof of breach or damages in this visit. Director-level documentation review of escalation rationale and risk discussion is the appropriate internal use of this memorandum.", "director_summary": "This oversight brief concerns a documented tirzepatide dose escalation after only one week on the prior dose, materially shorter than the commonly referenced multi-week step interval. Public authorities in the supplied corpus address GLP-1 manufacturing, compounding, and manufacturer products-liability aggregation, not clinic-level titration pacing. No retrieved record states a settlement, verdict, fine, or penalty amount applicable to accelerated titration in ambulatory care. The public signal is therefore contextual to the GLP-1 litigation and enforcement environment rather than proof of breach or damages in this visit. Director-level documentation review of escalation rationale and risk discussion is the appropriate internal use of this memorandum.", "report": { "matter": "Rapid tirzepatide titration — one-week step interval (Zepbound/Mounjaro)", "scope": "Single-visit clinical concern regarding dose escalation faster than label-aligned titration pacing, together with the vetted public reference_context only (FDA warning letters and CourtListener dockets/opinions). No chart beyond the supplied brief/evidence/note excerpt; no retained-counsel file review.", "facts_considered": "Male patient, age 41. Medication recorded as Zepbound/Mounjaro (tirzepatide) with escalation to 7.5 mg weekly. Structured field indicates weeks_on_current_dose=1 and medication.is_dose_escalation=true. Visit note excerpt states: “Escalating dose; 1 week on the prior dose.” Clinical brief describes escalation after only one week on the prior dose, below the recommended approximately four-week titration interval. Reasoning notes absence of charted justification for accelerated titration or a mitigation plan for increased gastrointestinal adverse-event risk.", "issue_presented": "Whether public-record patterns concerning GLP-1 products and related enforcement or products-liability activity inform medical-director oversight of documentation and process when a tirzepatide dose is escalated after a one-week interval rather than the longer step interval referenced on labeling knowledge materials—without treating manufacturer MDLs as clinic malpractice findings.", "analysis": "The supplied clinical concern is narrow: escalation after one week on the prior tirzepatide dose, with the note confirming that interval and no supplied justification for departure from the approximately four-week step cadence. Public items in reference_context do not interpret label titration schedules for prescribing clinicians and do not adjudicate ambulatory dosing decisions. Their relevance is limited to the broader regulatory and litigation environment surrounding GLP-1 receptor agonists, including tirzepatide.\n\nFDA warning correspondence in the corpus targets manufacturing deviations and online offering of compounded or unapproved GLP-1-related drugs, including tirzepatide offerings flagged as unapproved new drugs and misbranded products introduced into interstate commerce [2], and separate foreign manufacturing CGMP concerns [1]. Those letters illustrate active federal scrutiny of GLP-1 product quality and distribution channels; they do not address how quickly a labeled product may be titrated in a clinic visit and cannot be read as findings about this escalation.\n\nMultidistrict products-liability proceedings aggregate federal actions involving GLP-1 receptor agonists, including an MDL captioned for GLP-1 RA products liability [3] and a related streamlined docket concerning non-arteritic anterior ischemic optic neuropathy claims involving Eli Lilly [4]. Those dockets reflect manufacturer-directed product-liability aggregation and alleged injury theories at scale. They are not clinic-malpractice adjudications and do not establish standards of care for week-by-week titration intervals. Older secondary opinion material on a different manufacturer’s diabetes therapy [5] and a state healthcare-authority benefits opinion [6] likewise do not supply holdings on tirzepatide step timing. Accordingly, public authorities support only a qualitative backdrop of GLP-1 scrutiny; they do not bridge to a documented liability determination on this one-week escalation.", "observations": [ "[1] Public FDA warning activity in the corpus centers on GLP-1-related manufacturing and on websites offering compounded or unapproved agents including tirzepatide, indicating sustained regulatory attention to product channels rather than clinic titration charts [1][2].", "[2] Federal MDL activity aggregates numerous GLP-1 receptor agonist products-liability actions, including separate optic-neuropathy-focused proceedings, evidencing high-volume manufacturer-side litigation activity without stating clinic titration rules or damages figures [3][4].", "[3] None of the retrieved opinions or dockets sets out a holding that a one-week tirzepatide step, standing alone, constitutes negligence; the corpus is silent on dollar recoveries for accelerated titration claims." ], "limitations": "This memorandum does not review the full medical record, informed-consent materials, prior tolerability, prescriber rationale, patient-reported symptoms, or pharmacy dispensing history. It does not prove that this clinic or clinician violated any standard of care, that any adverse event occurred, or that any claim has been or will be filed. Manufacturer products-liability MDLs and FDA letters to unrelated entities are not findings about RubikMD or this visit. No patient outcome data are supplied.", "director_considerations": "Consider whether the chart should clearly document clinical rationale if titration proceeds faster than the labeled multi-week interval, including tolerability on the prior dose, patient counseling on gastrointestinal and other known risks of faster escalation, and any monitoring or follow-up plan. Consider concordance review between structured titration fields and free-text notes for oversight audits. This is process documentation guidance only, not a treatment directive or legal advice.", "risk_band": "limited" }, "exposure": { "summary": "Public exposure context is qualitative and manufacturer- or compounding-channel focused. Retrieved dockets show aggregated GLP-1 products-liability litigation activity, and FDA letters show enforcement against certain GLP-1 sellers and manufacturers. No supplied public record states a settlement, verdict, award, fine, or civil penalty amount tied to rapid outpatient titration of tirzepatide or to clinic dosing intervals.", "figures": [], "basis": "Analogy limited to class-level GLP-1 products-liability MDL presence [3][4] and FDA warning-letter enforcement posture on tirzepatide-related offerings and manufacturing [1][2]; no damages schedules or clinic-malpractice verdicts on titration pacing appear in reference_context.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, fine, or civil-penalty dollar amounts for rapid titration or for any clinic-level tirzepatide dosing claim. No figure is available to quote; figures remain empty. Filing fees and invented ranges are not used." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:47:54.318Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "body": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation\nCourt: United States Judicial Panel on Multidistrict Litigation\nDocket: MDL No. 3094\nFiled: 2023-12-01\nParties: Liaison Counsel for Plaintiffs; Liaison Counsel for Defendants Filing: Brief — Case MDL No. 3094 Document 1-1 Filed 12/01/23 Page 1 of 21 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLP-1 RECEPTOR AGONIST CASES MDL DOCKET NO.______ MEMORANDUM IN SUPPORT OF PLAINTIFFS’ MOTION FOR TRANSFER OF ACTIONS TO THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA PURSUANT TO 28 U.S.C. § Filing: Response to Motion to Transfer — Case MDL No. 3094 Document 58 Filed 12/29/23 Page 1 of 24 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLUCAGON-LIKE PEPTIDE-1 MDL No. 3094 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATI" }, { "n": 4, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Jeannette Simonton, V. Washington State Health Care Authority", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10852801/jeannette-simonton-v-washington-state-health-care-authority/", "body": "Jeannette Simonton, V. Washington State Health Care Authority\nCourt: Court of Appeals of Washington\nDocket: 86988-4\nFiled: 2026-05-04\nIN THE COURT OF APPEALS OF THE STATE OF WASHINGTON JEANNETTE SIMONTON and RYAN KELSO, each on their own behalf and No. 86988-4-I on behalf of similarly situated others, DIVISION ONE Appellants, PUBLISHED OPINION v. WASHINGTON STATE HEALTH CARE AUTHORITY; and SUE BIRCH, director of the Washington State Health Care Authority and chair of t" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0012", "priority": "medium", "title": "Compounded GLP-1 without disclosure", "full_message": "Compounded semaglutide used; no documented patient disclosure of non-FDA-approved compounded formulation", "patient_label": "Male, 49", "visit_date": "2026-07-08", "medication": "compounded semaglutide 0.25 mg weekly", "flag_code": "E_COMPOUNDED_NO_DISCLOSURE", "rule_id": "R14", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA alerts on compounded semaglutide/tirzepatide (non-FDA-approved); disclosure expected.", "guideline_quote": "FDA alerts on compounded semaglutide/tirzepatide (non-FDA-approved); disclosure expected.", "source_snippet": "On compounded semaglutide 0.25 mg weekly", "evidence_field": "Agent evidence", "evidence_raw": "medication.is_compounded=true; note: 'On compounded semaglutide 0.25 mg weekly' and 'Informed consent for GLP-1 therapy obtained' (no compounded/non-FDA-approved disclosure)", "evidence_label": "medication.is_compounded=true; note: 'On compounded semaglutide 0.25 mg weekly' and 'Informed consent for GLP-1 therapy obtained' (no compounded/non-FDA-approved disclosure)", "why": "Compounded semaglutide used; no documented patient disclosure of non-FDA-approved compounded formulation", "note": "Encounter SYN-0012\nPatient: Male, 49 · BMI 34.5\nComorbidities: hypertension, dyslipidemia, OSA\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: compounded semaglutide, 0.25 mg weekly (new start)\nLabs: HbA1c 6.0; eGFR 114\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: no\n\nClinician note\nNew-start visit. 49yo M on GLP-1 for weight management, BMI 34.5. On compounded semaglutide 0.25 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 6.0%, eGFR 114, ALT 26, TSH 2.17. Informed consent for GLP-1 therapy obtained and documented. No new GI symptoms reported. Follow-up scheduled in 42 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:09:30.807Z", "independent_summary": "Chart is largely protocol-concordant except missing documentation that compounded semaglutide was disclosed to the patient.", "reasoning_trace": [ "Reviewed structured history: no MTC/MEN2/pancreatitis flags; note confirms MTC/MEN2 screening.", "Male patient age 49—pregnancy status not applicable; no E_MISSING_PREGNANCY_STATUS.", "BMI 34.5, HbA1c 6.0%, eGFR 114 present; meets weight-management eligibility; no insulin/sulfonylurea co-therapy.", "New start at 0.25 mg with follow-up in 42 days; no rapid titration or dose-escalation follow-up gap.", "Prior weight-loss attempts and general GLP-1 consent documented.", "Flagged E_COMPOUNDED_NO_DISCLOSURE because compounded product is used without documented compounded-specific patient disclosure.", "Did not flag eating disorder, pancreatitis, or drug-interaction codes—no chart evidence; reference_context unused for flag justification." ], "reasoning_steps": [ "Observed: Structured medication.is_compounded=true and note states patient is on compounded semaglutide 0.25 mg weekly.", "Source: Knowledge card requires that compounded (non-FDA-approved) formulations be disclosed to the patient; reference_context [1]-[3] are general GLP-1 efficacy/safety reviews and do not address compounded disclosure.", "Gap: Note documents general GLP-1 informed consent only; it does not document that the patient was informed this is a compounded, non-FDA-approved product versus FDA-approved Wegovy.", "Conclusion: A medical director should confirm compounded-product risks, sourcing, and alternatives were explicitly discussed—not assumed from general GLP-1 consent." ], "agent_message": "Compounded semaglutide used; no documented patient disclosure of non-FDA-approved compounded formulation", "agent_evidence": "medication.is_compounded=true; note: 'On compounded semaglutide 0.25 mg weekly' and 'Informed consent for GLP-1 therapy obtained' (no compounded/non-FDA-approved disclosure)", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 3, "title": "A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. (glp1-semaglutide §abstract; DOI 10.7759/cureus.107970)", "body": "Obesity is an increasingly growing public health issue affecting a substantial proportion of the population in the United States. This condition increases the risk for multiple disease processes, including cardiometabolic disorders, osteoarthritis, gout, respiratory issues, reproductive problems,..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_COMPOUNDED_NO_DISCLOSURE", "severity": "medium", "message": "Compounded semaglutide used; no documented patient disclosure of non-FDA-approved compounded formulation", "evidence": "medication.is_compounded=true; note: 'On compounded semaglutide 0.25 mg weekly' and 'Informed consent for GLP-1 therapy obtained' (no compounded/non-FDA-approved disclosure)", "reasoning_steps": [ "Observed: Structured medication.is_compounded=true and note states patient is on compounded semaglutide 0.25 mg weekly.", "Source: Knowledge card requires that compounded (non-FDA-approved) formulations be disclosed to the patient; reference_context [1]-[3] are general GLP-1 efficacy/safety reviews and do not address compounded disclosure.", "Gap: Note documents general GLP-1 informed consent only; it does not document that the patient was informed this is a compounded, non-FDA-approved product versus FDA-approved Wegovy.", "Conclusion: A medical director should confirm compounded-product risks, sourcing, and alternatives were explicitly discussed—not assumed from general GLP-1 consent." ] } ], "rules_codes": [ "E_COMPOUNDED_NO_DISCLOSURE" ] }, "liability_pack": { "flag": { "request_id": "SYN-0012", "error_code": "E_COMPOUNDED_NO_DISCLOSURE", "message": "Compounded semaglutide used; no documented patient disclosure of non-FDA-approved compounded formulation", "evidence": "medication.is_compounded=true; note: 'On compounded semaglutide 0.25 mg weekly' and 'Informed consent for GLP-1 therapy obtained' (no compounded/non-FDA-approved disclosure)", "note_excerpt": "On compounded semaglutide 0.25 mg weekly", "clinical_brief": "Chart is largely protocol-concordant except missing documentation that compounded semaglutide was disclosed to the patient.", "clinical_title": "Compounded GLP-1 without disclosure", "medication": "compounded semaglutide 0.25 mg weekly" }, "liability": { "request_id": "SYN-0012", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_COMPOUNDING", "THEME_REGULATORY_ENFORCEMENT", "THEME_FAILURE_TO_WARN" ], "relevance": "Directly addresses compounded semaglutide offerings as a regulatory concern, supporting oversight focus on compounded versus FDA-approved product characterization for this visit’s missing disclosure documentation [2].", "used_part": "FDA reviewed website content offering various compounded drug products, including retatrutide, semaglutide and tirzepatide; letter states products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce.", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (MDL No. 3094)", "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "date": "2023-12-01", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Shows sustained federal multidistrict product-liability attention to GLP-1 receptor agonists, providing public-context backdrop for risk-communication sensitivity; not a clinic-malpractice holding for this visit [4].", "used_part": "Judicial Panel on Multidistrict Litigation materials captioned IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, including plaintiffs’ motion for transfer under 28 U.S.C. § 1407.", "citation_tag": "[4]" }, { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Illustrates additional public GLP-1 products-liability consolidation activity (NAION-related), reinforcing system-level litigation attention to GLP-1 product risks without speaking to this clinic’s disclosure documentation [3].", "used_part": "E.D. Pennsylvania streamlined docket materials and JPML transfer order language consolidating GLP-1 RAs non-arteritic anterior ischemic optic neuropathy products liability actions.", "citation_tag": "[3]" } ], "executive_summary": "This oversight brief addresses a single visit concern: use of compounded semaglutide with charted general GLP-1 consent but no documented disclosure that the product is a compounded, non-FDA-approved formulation. Public authorities in the supplied corpus reflect active FDA enforcement against marketers of compounded GLP-1 products and large manufacturer-focused GLP-1 products-liability MDLs; they do not adjudicate this clinic or visit. No settlement, verdict, fine, or civil-penalty dollar amounts appear in the retrieved public records. The public-record signal supports director-level review of compounded-product disclosure documentation, without any finding of liability.", "director_summary": "This oversight brief addresses a single visit concern: use of compounded semaglutide with charted general GLP-1 consent but no documented disclosure that the product is a compounded, non-FDA-approved formulation. Public authorities in the supplied corpus reflect active FDA enforcement against marketers of compounded GLP-1 products and large manufacturer-focused GLP-1 products-liability MDLs; they do not adjudicate this clinic or visit. No settlement, verdict, fine, or civil-penalty dollar amounts appear in the retrieved public records. The public-record signal supports director-level review of compounded-product disclosure documentation, without any finding of liability.", "report": { "matter": "Compounded semaglutide — missing non-FDA-approved product disclosure documentation", "scope": "Review limited to this visit’s clinical_brief, message, evidence, and note_excerpt regarding compounded semaglutide without compounded-product disclosure, together with the public warning letters, dockets, opinion, and recall supplied in reference_context only.", "facts_considered": "Structured data indicate medication.is_compounded=true. The note states the patient is on compounded semaglutide 0.25 mg weekly and that informed consent for GLP-1 therapy was obtained. The supplied materials do not document that the patient was told the formulation is compounded and non-FDA-approved, as distinct from an FDA-approved semaglutide product. Patient label: male, 49. Chart is otherwise described as largely protocol-concordant.", "issue_presented": "Whether, for oversight purposes, absence of documented disclosure that the dispensed semaglutide is a compounded, non-FDA-approved product—versus reliance on general GLP-1 informed consent—presents a process and failure-to-inform documentation gap in light of public compounding and GLP-1 enforcement and litigation patterns.", "analysis": "The visit record affirmatively identifies compounded semaglutide and general GLP-1 consent, but does not document counseling that the product is compounded and not FDA-approved. Public FDA correspondence in the corpus addresses compounded GLP-1 offerings directly. In the GLP-1 Solution warning letter, FDA states that it reviewed website content offering various compounded drug products, including semaglutide and tirzepatide, and advises that specified products are unapproved new drugs and misbranded drugs introduced into interstate commerce [2]. That enforcement posture underscores regulatory sensitivity to compounded GLP-1 products as a category distinct from approved branded agents, which is the distinction missing from this visit’s documented consent language.\n\nSeparately, the corpus includes multidistrict product-liability dockets concerning GLP-1 receptor agonists, including MDL No. 3094 and a streamlined NAION-related docket in the Eastern District of Pennsylvania [3][4]. Those matters are manufacturer- and product-focused diversity/product-liability consolidations; they are not clinic-malpractice adjudications and do not establish duties or breaches for this visit. They do, however, illustrate sustained public litigation attention to GLP-1 risk communication and product characterization at a system level.\n\nOther supplied authorities are more attenuated. The Harbin Jixianglong warning letter concerns CGMP deviations at a foreign drug manufacturing facility [1]; the Seufert opinion addresses summary judgment in an older diabetes-drug products case [5]; and the Cardinal Health openFDA entry is a temperature-abuse recall of branded Wegovy [6]. None supplies a dollar recovery figure or a holding that this clinic’s documentation was inadequate. The oversight value of the corpus is therefore analogical: public enforcement treats compounded GLP-1s as a regulated, disclosure-sensitive category, while this chart documents compounding in the medication line without a parallel compounded/non-FDA-approved disclosure note.", "observations": [ "[1] FDA warning-letter activity in the corpus expressly targets firms offering compounded GLP-1 products (including semaglutide), framing them as unapproved and/or misbranded in interstate commerce [2].", "[2] Parallel public GLP-1 products-liability MDL activity reflects large-scale litigation focus on GLP-1 risk and product issues, distinct from any clinic-level malpractice determination [3][4].", "[3] No supplied public record states a settlement, verdict, fine, or civil-penalty amount tied to compounded-GLP-1 disclosure failures at a prescribing clinic." ], "limitations": "This memorandum does not prove that the clinic failed to obtain informed consent, that the patient was uninformed, that the compounded product was adulterated or misbranded, or that any statute or standard of care was breached. Public MDLs and warning letters do not adjudicate this visit, this prescriber, or this pharmacy source. Manufacturer product-liability consolidations are not equivalent to clinic malpractice findings. No patient outcome, sourcing chain, or full consent packet was available beyond the supplied excerpt.", "director_considerations": "Consider whether the medical record template for compounded GLP-1s captures explicit discussion of compounded status, non-FDA-approved nature, material differences from approved products, sourcing, and alternatives, separate from generic GLP-1 therapy consent. Consider periodic chart audit sampling where medication.is_compounded=true for presence of that disclosure language. Consider aligning patient-facing materials with current public FDA compounding communications. No treatment or settlement recommendation is made.", "risk_band": "moderate" }, "exposure": { "summary": "Public exposure context for this concern is qualitative. FDA has issued warning letters addressing compounded GLP-1 product offerings, including semaglutide [2], and GLP-1 receptor agonist products remain the subject of federal MDL consolidations [3][4]. The retrieved corpus does not state any settlement, verdict, award, fine, or civil-penalty dollar figures applicable to clinic-level compounded-product disclosure gaps. No figure should be read as this clinic’s expected loss.", "figures": [], "basis": "Analogy to FDA warning-letter enforcement posture on compounded GLP-1 offerings [2] and to manufacturer-focused GLP-1 products-liability MDL dockets [3][4]; no public dollar recoveries in the supplied set.", "confidence": "none", "transparency_note": "Retrieved public records do not state settlement, verdict, fine, or civil-penalty amounts for compounded-semaglutide disclosure failures or for this clinic. No dollar exposure figure is available from reference_context." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:48:36.247Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "body": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation\nCourt: United States Judicial Panel on Multidistrict Litigation\nDocket: MDL No. 3094\nFiled: 2023-12-01\nParties: Liaison Counsel for Plaintiffs; Liaison Counsel for Defendants Filing: Brief — Case MDL No. 3094 Document 1-1 Filed 12/01/23 Page 1 of 21 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLP-1 RECEPTOR AGONIST CASES MDL DOCKET NO.______ MEMORANDUM IN SUPPORT OF PLAINTIFFS’ MOTION FOR TRANSFER OF ACTIONS TO THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA PURSUANT TO 28 U.S.C. § Filing: Response to Motion to Transfer — Case MDL No. 3094 Document 58 Filed 12/29/23 Page 1 of 24 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLUCAGON-LIKE PEPTIDE-1 MDL No. 3094 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATI" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "FDA recall D-0393-2025: Cardinal Health Inc.", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0393-2025: Cardinal Health Inc.\nWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released." } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0013", "priority": "medium", "title": "Pregnancy status not documented", "full_message": "Pregnancy status not documented for childbearing-age female starting GLP-1", "patient_label": "Female, 41", "visit_date": "2026-07-09", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly", "flag_code": "E_MISSING_PREGNANCY_STATUS", "rule_id": "R03", "rulebook": "fda_label", "rulebook_label": "FDA label", "source_cite": "FDA label: Use in Specific Populations: not recommended in pregnancy; document status in childbearing-potential patients.", "guideline_quote": "FDA label: Use in Specific Populations: not recommended in pregnancy; document status in childbearing-potential patients.", "source_snippet": "Pregnancy status: not documented (F, age 41).", "evidence_field": "Agent evidence", "evidence_raw": "patient.sex=F, patient.pregnant=null; doctor_report note_text contains no pregnancy, contraception, or childbearing-potential assessment", "evidence_label": "patient.sex=F, patient.pregnant=null; doctor_report note_text contains no pregnancy, contraception, or childbearing-potential assessment", "why": "Pregnancy status not documented for childbearing-age female starting GLP-1", "note": "Encounter SYN-0013\nPatient: Female, 41 · BMI 46.0\nComorbidities: NAFLD\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: no\nMedication: Zepbound / Mounjaro (tirzepatide), 2.5 mg weekly (new start)\nLabs: HbA1c 5.9; eGFR 102\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nNew-start visit. 41yo F on GLP-1 for weight management, BMI 46.0. On Zepbound (tirzepatide) 2.5 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 5.9%, eGFR 102, ALT 27, TSH 1.23. Informed consent for GLP-1 therapy obtained and documented. Reports diarrhea, constipation; counseled on management. Follow-up scheduled in 56 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:08:51.656Z", "independent_summary": "Chart is otherwise protocol-concordant for new-start tirzepatide, but pregnancy status for this 41-year-old female was not documented.", "reasoning_trace": [ "Structured and narrative data show new-start Zepbound 2.5 mg with BMI 46, NAFLD comorbidity, baseline HbA1c 5.9%, eGFR 102, informed consent, prior weight-loss attempts, and 56-day follow-up — meeting eligibility and baseline workup expectations [2].", "MTC/MEN2/pancreatitis screens are negative in structured history and explicitly documented in the note; no E_CONTRAINDICATION_MTC, E_NO_MEN2_SCREEN, or E_PANCREATITIS_HISTORY basis.", "No insulin, sulfonylurea, compounded product, eating-disorder history, or dose escalation — E_INSULIN_INTERACTION, E_COMPOUNDED_NO_DISCLOSURE, E_EATING_DISORDER_HISTORY, E_RAPID_TITRATION, and E_DOSE_ESCALATION_NO_FOLLOWUP not applicable.", "For a 41-year-old female, patient.pregnant=null and the note omit pregnancy assessment despite knowledge-card requirement — flagged E_MISSING_PREGNANCY_STATUS.", "reference_context [2] supported eligibility review; pregnancy concern derived from knowledge card, not reference_context excerpts." ], "reasoning_steps": [ "Observed: 41-year-old female with patient.pregnant=null and no pregnancy-related language in doctor_report.note_text.", "Source: Knowledge card — pregnancy not recommended with GLP-1/GIP therapy; pregnancy status should be addressed for people of childbearing potential.", "Gap: Note documents consent, MTC/MEN2 screening, and follow-up but does not record pregnancy status, testing, or contraception counseling.", "Conclusion: Unverified pregnancy status before initiating tirzepatide is a director-facing safety documentation gap, not a diagnosis." ], "agent_message": "Pregnancy status not documented for childbearing-age female starting GLP-1", "agent_evidence": "patient.sex=F, patient.pregnant=null; doctor_report note_text contains no pregnancy, contraception, or childbearing-potential assessment", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." }, { "n": 3, "title": "FDA label (tirzepatide) - Indications And Usage [part 2] (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_MISSING_PREGNANCY_STATUS", "severity": "medium", "message": "Pregnancy status not documented for childbearing-age female starting GLP-1", "evidence": "patient.sex=F, patient.pregnant=null; doctor_report note_text contains no pregnancy, contraception, or childbearing-potential assessment", "reasoning_steps": [ "Observed: 41-year-old female with patient.pregnant=null and no pregnancy-related language in doctor_report.note_text.", "Source: Knowledge card — pregnancy not recommended with GLP-1/GIP therapy; pregnancy status should be addressed for people of childbearing potential.", "Gap: Note documents consent, MTC/MEN2 screening, and follow-up but does not record pregnancy status, testing, or contraception counseling.", "Conclusion: Unverified pregnancy status before initiating tirzepatide is a director-facing safety documentation gap, not a diagnosis." ] } ], "rules_codes": [ "E_MISSING_PREGNANCY_STATUS" ] }, "liability_pack": { "flag": { "request_id": "SYN-0013", "error_code": "E_MISSING_PREGNANCY_STATUS", "message": "Pregnancy status not documented for childbearing-age female starting GLP-1", "evidence": "patient.sex=F, patient.pregnant=null; doctor_report note_text contains no pregnancy, contraception, or childbearing-potential assessment", "note_excerpt": "Pregnancy status: not documented (F, age 41).", "clinical_brief": "Chart is otherwise protocol-concordant for new-start tirzepatide, but pregnancy status for this 41-year-old female was not documented.", "clinical_title": "Pregnancy status not documented", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly" }, "liability": { "request_id": "SYN-0013", "related": [ { "item_type": "court_docket", "title": "IN RE: GLP-1 RAs Products Liability Litigation (MDL No. 3094)", "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "date": "2023-12-01", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Cited solely to note the existence of consolidated manufacturer products-liability activity around the GLP-1 class; it does not address clinic pregnancy-status documentation and is not used as a malpractice analogue for this visit [4].", "used_part": "MDL caption and transfer briefing identifying In re Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094.", "citation_tag": "[4]" }, { "item_type": "warning_letter", "title": "GLP-1 Solution — FDA Warning Letter 715883", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_COMPOUNDING" ], "relevance": "Shows FDA enforcement attention to tirzepatide and other GLP-1-related products offered online as compounded/unapproved drugs; used only as regulatory-context backdrop, not as authority on pregnancy charting [2].", "used_part": "FDA observed website offering compounded drug products including retatrutide, semaglutide and tirzepatide; retatrutide products characterized as unapproved new drugs and misbranded drugs in interstate commerce.", "citation_tag": "[2]" }, { "item_type": "warning_letter", "title": "Harbin Jixianglong Biotech Co., Ltd. — FDA Warning Letter 723330", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "date": "2026-05-01", "themes": [ "THEME_REGULATORY_ENFORCEMENT" ], "relevance": "Illustrates CGMP/manufacturing enforcement in the broader drug supply chain; included to confirm that retrieved FDA letters do not speak to clinic pregnancy-status documentation for this concern [1].", "used_part": "Warning letter summarizing significant deviations from Current Good Manufacturing practice following FDA inspection of the Harbin facility (Nov. 3–7, 2025).", "citation_tag": "[1]" } ], "executive_summary": "This oversight brief addresses a single documentation concern: pregnancy status was not recorded for a 41-year-old female before new-start tirzepatide, despite an otherwise protocol-concordant chart. The vetted public corpus contains GLP-1-related product-liability multidistrict activity and FDA warning letters directed at manufacturing and compounded-product marketing, none of which adjudicate clinic-level pregnancy screening or charting duties. No settlement, verdict, fine, or penalty amounts in the supplied records attach to missing pregnancy-status documentation. Public-record support for a liability analogy to this visit is therefore weak. Risk signaling is insufficient on the authorities retrieved.", "director_summary": "This oversight brief addresses a single documentation concern: pregnancy status was not recorded for a 41-year-old female before new-start tirzepatide, despite an otherwise protocol-concordant chart. The vetted public corpus contains GLP-1-related product-liability multidistrict activity and FDA warning letters directed at manufacturing and compounded-product marketing, none of which adjudicate clinic-level pregnancy screening or charting duties. No settlement, verdict, fine, or penalty amounts in the supplied records attach to missing pregnancy-status documentation. Public-record support for a liability analogy to this visit is therefore weak. Risk signaling is insufficient on the authorities retrieved.", "report": { "matter": "Missing pregnancy-status documentation — tirzepatide new start (female, age 41)", "scope": "Review limited to the supplied clinical concern (missing pregnancy status on tirzepatide initiation) and the vetted public reference_context items only (FDA warning letters, GLP-1 MDL docket materials, and unrelated court opinions/dockets). No clinic file, label full text, or external research was reviewed.", "facts_considered": "Chart is described as otherwise protocol-concordant for new-start tirzepatide 2.5 mg weekly (Zepbound/Mounjaro). Patient is female, age 41. Evidence states patient.sex=F and patient.pregnant=null. Doctor-report note text contains no pregnancy, contraception, or childbearing-potential assessment. Note excerpt: “Pregnancy status: not documented (F, age 41).” Reasoning notes that consent, MTC/MEN2 screening, and follow-up were documented, but pregnancy status, testing, or contraception counseling was not.", "issue_presented": "Whether failure to document pregnancy status (or related contraception/childbearing-potential assessment) before initiating tirzepatide in a woman of childbearing age presents a director-facing process and documentation oversight issue when viewed against publicly available GLP-1 enforcement and litigation records.", "analysis": "The clinical concern is narrow and documentation-centered: for a 41-year-old female starting tirzepatide, pregnancy status is null in structured data and absent from the narrative note, while other protocol elements were recorded. Public authorities supplied in reference_context do not decide, or even discuss, clinic obligations to assess or chart pregnancy status before GLP-1/GIP therapy. They therefore supply only remote contextual backdrop, not a holding applicable to this visit.\n\nThe principal class-wide public docket is the GLP-1 receptor agonist products-liability MDL, which consolidates manufacturer-focused product-liability actions rather than medical-malpractice or documentation claims against prescribing clinics [4]. That docket signals sustained civil activity around the GLP-1 product class, but it is not authority for a standard of care on pregnancy screening or chart completeness at the point of care, and it is not a finding about this clinic.\n\nFDA warning letters in the corpus address foreign manufacturing CGMP deviations [1] and online offering of compounded or unapproved GLP-1-related drugs including tirzepatide [2]. Those letters reflect regulatory enforcement posture toward manufacturing quality and unapproved/misbranded distribution. They do not articulate requirements for documenting pregnancy status in an outpatient prescribing note. Other retrieved items—trademark litigation against a weight-loss entity [3], an older incretin product-liability summary-judgment opinion [5], and a state health-care authority benefits opinion [6]—likewise do not speak to pregnancy-status documentation before tirzepatide initiation.\n\nAccordingly, the public record as supplied supports only a limited observation that GLP-1 products attract regulatory and product-liability attention; it does not ground a public-pattern finding that missing pregnancy documentation in this chart mirrors adjudicated clinic liability.", "observations": [ "[1] Public GLP-1-related civil activity in the corpus is dominated by manufacturer products-liability multidistrict consolidation (MDL No. 3094), not by published malpractice opinions on pregnancy-status charting at initiation [4].", "[2] FDA warning letters retrieved concern manufacturing deviations and compounded/unapproved GLP-1 marketing (including tirzepatide offerings), not clinic screening or documentation of pregnancy status [1][2].", "[3] No supplied public opinion, docket entry, or warning letter states a holding, fine, or settlement tied to undocumented pregnancy status before tirzepatide or other GLP-1 therapy." ], "limitations": "This memorandum does not prove negligence, malpractice, regulatory violation, or causation as to this clinic or this visit. It does not review the full medical record, informed-consent forms, pharmacy records, lab orders, or actual prescribing label counseling. Public MDL and warning-letter materials are not findings about RubikMD or this patient. Absence of pregnancy language in the supplied excerpt is a documentation gap description only; it does not establish that the patient was pregnant, that harm occurred, or that counseling did not occur off-note. No predictive statement is made about suit, board action, or loss value.", "director_considerations": "Consider whether new-start tirzepatide templates for females of childbearing potential prompt structured capture of pregnancy status, recent testing if used, and any contraception discussion when clinically appropriate, consistent with internal protocol. Consider a targeted chart audit sample for similar new starts to confirm whether pregnancy-status fields are completed when other protocol elements (consent, MTC/MEN2, follow-up) are already documented. Any review should remain documentation- and process-focused; this brief does not recommend clinical management changes or legal strategy.", "risk_band": "insufficient" }, "exposure": { "summary": "Supplied public records do not state settlement, verdict, award, fine, or civil-penalty amounts linked to missing pregnancy-status documentation before tirzepatide. Qualitative public context includes an active GLP-1 products-liability MDL directed at manufacturers [4] and FDA warning activity around compounded or unapproved GLP-1 products [2], neither of which quantifies clinic exposure for this documentation concern. No public dollar figure in the corpus is applicable to this visit.", "figures": [], "basis": "Analogy attempted only to class-level GLP-1 product-liability docket presence [4] and FDA compounding/manufacturing warning letters [1][2]; no record supplies a damages, settlement, or penalty figure for pregnancy-documentation omissions in clinic care.", "confidence": "none", "transparency_note": "Retrieved public records do not state any settlement, verdict, fine, or penalty amounts applicable to missing pregnancy status or similar clinic documentation gaps. No dollar exposure figure is available from reference_context; figures remain empty." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:48:45.795Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Novo Nordisk A/S v. New England Weight Loss, LLC", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/69873291/novo-nordisk-as-v-new-england-weight-loss-llc/", "body": "Novo Nordisk A/S v. New England Weight Loss, LLC\nCourt: District Court, D. New Hampshire\nDocket: 1:25-cv-00141\nFiled: 2025-04-10\nCause: 15:1051 Trademark Infringement Parties: Novo Nordisk A/S; New England Weight Loss, LLC Filing: Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 11 Filed 10/17/25 Page 1 of 21 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 1:25-cv-00141-SE-AJ New England Weight Loss, LLC REPORT AND RECOMMENDATION Plaintiffs, Novo Nordisk A/S and Novo No Filing: Complaint - New Case Filing: Order on Motion for Default Judgment AND Order on Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 12 Filed 11/18/25 Page 1 of 2 UNITED STATES DISTRICT COURT DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 25-cv-141-SE-AJ New England Weight Loss, LLC ORDER N\nReport and Recommendation: Case 1:25" }, { "n": 4, "title": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68082231/in-re-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-products/", "body": "IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation\nCourt: United States Judicial Panel on Multidistrict Litigation\nDocket: MDL No. 3094\nFiled: 2023-12-01\nParties: Liaison Counsel for Plaintiffs; Liaison Counsel for Defendants Filing: Brief — Case MDL No. 3094 Document 1-1 Filed 12/01/23 Page 1 of 21 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLP-1 RECEPTOR AGONIST CASES MDL DOCKET NO.______ MEMORANDUM IN SUPPORT OF PLAINTIFFS’ MOTION FOR TRANSFER OF ACTIONS TO THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF LOUISIANA PURSUANT TO 28 U.S.C. § Filing: Response to Motion to Transfer — Case MDL No. 3094 Document 58 Filed 12/29/23 Page 1 of 24 BEFORE THE UNITED STATES JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: GLUCAGON-LIKE PEPTIDE-1 MDL No. 3094 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATI" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Jeannette Simonton, V. Washington State Health Care Authority", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10852801/jeannette-simonton-v-washington-state-health-care-authority/", "body": "Jeannette Simonton, V. Washington State Health Care Authority\nCourt: Court of Appeals of Washington\nDocket: 86988-4\nFiled: 2026-05-04\nIN THE COURT OF APPEALS OF THE STATE OF WASHINGTON JEANNETTE SIMONTON and RYAN KELSO, each on their own behalf and No. 86988-4-I on behalf of similarly situated others, DIVISION ONE Appellants, PUBLISHED OPINION v. WASHINGTON STATE HEALTH CARE AUTHORITY; and SUE BIRCH, director of the Washington State Health Care Authority and chair of t" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0038", "priority": "medium", "title": "Missing baseline HbA1c at start", "full_message": "New GLP-1 start without documented baseline HbA1c", "patient_label": "Female, 51", "visit_date": "2026-07-07", "medication": "Wegovy / Ozempic (semaglutide) 0.5 mg weekly", "flag_code": "E_MISSING_BASELINE_HBA1C", "rule_id": "R05", "rulebook": "guideline", "rulebook_label": "Society guideline / intake standard", "source_cite": "Standard diabetes/obesity intake; ADA Standards of Care: baseline glycemic assessment.", "guideline_quote": "Standard diabetes/obesity intake; ADA Standards of Care: baseline glycemic assessment.", "source_snippet": "Baseline HbA1c not documented at new start (eGFR on chart: 81).", "evidence_field": "Agent evidence", "evidence_raw": "labs.hba1c_percent=null; medication.is_new_start=true; note: 'Labs: eGFR 81, ALT 31, TSH 2.38' (no HbA1c)", "evidence_label": "labs.hba1c_percent=null; medication.is_new_start=true; note: 'Labs: eGFR 81, ALT 31, TSH 2.38' (no HbA1c)", "why": "New GLP-1 start without documented baseline HbA1c", "note": "Encounter SYN-0038\nPatient: Female, 51 · BMI 35.0\nComorbidities: none listed\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Wegovy / Ozempic (semaglutide), 0.5 mg weekly (new start)\nLabs: HbA1c not documented; eGFR 81\nFollow-up scheduled: yes\nInformed consent documented: yes\nCompounded disclosure documented: yes\n\nClinician note\nFollow-up visit. 51yo F on GLP-1 for weight management, BMI 35.0. On Wegovy (semaglutide) 0.5 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Pregnancy status reviewed; not pregnant, contraception discussed. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: eGFR 81, ALT 31, TSH 2.38. Informed consent for GLP-1 therapy obtained and documented. No new GI symptoms reported. Follow-up scheduled in 56 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "hybrid", "model": "composer-2.5", "run_at": "2026-07-20T19:10:26.316Z", "independent_summary": "New semaglutide start is otherwise well documented, but baseline HbA1c is missing from labs and the note.", "reasoning_trace": [ "Reviewed MTC/MEN2: personal_history_mtc=false, family_history_mtc=false, men2=false, and note documents screening — no E_CONTRAINDICATION_MTC or E_NO_MEN2_SCREEN.", "Reviewed pregnancy status for 51yo F: patient.pregnant=false and note documents review with contraception discussion — no E_MISSING_PREGNANCY_STATUS.", "Reviewed pancreatitis, eating-disorder, and insulin/sulfonylurea interaction classes: no chart evidence — no E_PANCREATITIS_HISTORY, E_EATING_DISORDER_HISTORY, or E_INSULIN_INTERACTION.", "Reviewed eligibility and renal baseline: BMI 35 meets threshold; eGFR 81 present — no BMI or renal flags; hba1c_percent null on is_new_start=true — flagged E_MISSING_BASELINE_HBA1C.", "Reviewed titration and follow-up: starting 0.5 mg (not dose escalation); follow_up_scheduled=true at 56 days; consent and prior weight-loss attempts documented — no E_RAPID_TITRATION, E_DOSE_ESCALATION_NO_FOLLOWUP, E_NO_FOLLOWUP_PLAN, E_NO_CONSENT, or E_MISSING_PRIOR_ATTEMPTS.", "reference_context [1][2][3] was general literature background and did not identify additional chart-specific safety gaps beyond the knowledge card." ], "reasoning_steps": [ "Observed: Structured labs show hba1c_percent=null; medication.is_new_start=true; physician note lists eGFR, ALT, and TSH only with no HbA1c value or order.", "Source: Knowledge card — new start workup requires baseline HbA1c and renal function (eGFR); reference_context [1][3] provides general GLP-1 background but does not alter this baseline-lab requirement.", "Gap: Baseline glycemic assessment is absent from structured data and free-text documentation despite initiating Wegovy 0.5 mg weekly today.", "Conclusion: Incomplete new-start metabolic workup; medical director should confirm whether HbA1c was obtained outside the chart or needs to be ordered before continuing titration." ], "agent_message": "New GLP-1 start without documented baseline HbA1c", "agent_evidence": "labs.hba1c_percent=null; medication.is_new_start=true; note: 'Labs: eGFR 81, ALT 31, TSH 2.38' (no HbA1c)", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. (glp1-cardio-renal §abstract; DOI 10.1053/j.ajkd.2026.04.007)", "body": "Rationale & objective: Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1..." }, { "n": 3, "title": "A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. (glp1-semaglutide §abstract; DOI 10.7759/cureus.107970)", "body": "Obesity is an increasingly growing public health issue affecting a substantial proportion of the population in the United States. This condition increases the risk for multiple disease processes, including cardiometabolic disorders, osteoarthritis, gout, respiratory issues, reproductive problems,..." } ], "kb_cited": [], "all_agent_flags": [ { "error_code": "E_MISSING_BASELINE_HBA1C", "severity": "medium", "message": "New GLP-1 start without documented baseline HbA1c", "evidence": "labs.hba1c_percent=null; medication.is_new_start=true; note: 'Labs: eGFR 81, ALT 31, TSH 2.38' (no HbA1c)", "reasoning_steps": [ "Observed: Structured labs show hba1c_percent=null; medication.is_new_start=true; physician note lists eGFR, ALT, and TSH only with no HbA1c value or order.", "Source: Knowledge card — new start workup requires baseline HbA1c and renal function (eGFR); reference_context [1][3] provides general GLP-1 background but does not alter this baseline-lab requirement.", "Gap: Baseline glycemic assessment is absent from structured data and free-text documentation despite initiating Wegovy 0.5 mg weekly today.", "Conclusion: Incomplete new-start metabolic workup; medical director should confirm whether HbA1c was obtained outside the chart or needs to be ordered before continuing titration." ] } ], "rules_codes": [ "E_MISSING_BASELINE_HBA1C" ] }, "liability_pack": { "flag": { "request_id": "SYN-0038", "error_code": "E_MISSING_BASELINE_HBA1C", "message": "New GLP-1 start without documented baseline HbA1c", "evidence": "labs.hba1c_percent=null; medication.is_new_start=true; note: 'Labs: eGFR 81, ALT 31, TSH 2.38' (no HbA1c)", "note_excerpt": "Baseline HbA1c not documented at new start (eGFR on chart: 81).", "clinical_brief": "New semaglutide start is otherwise well documented, but baseline HbA1c is missing from labs and the note.", "clinical_title": "Missing baseline HbA1c at start", "medication": "Wegovy / Ozempic (semaglutide) 0.5 mg weekly" }, "liability": { "request_id": "SYN-0038", "related": [ { "item_type": "warning_letter", "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "date": "2025-09-09", "themes": [ "THEME_COMPOUNDING", "THEME_REGULATORY_ENFORCEMENT" ], "relevance": "Used only to note FDA enforcement attention on semaglutide-related compounded/unapproved offerings; it does not address baseline HbA1c documentation at a clinic new start [2].", "used_part": "FDA reviewed website content offering compounded drug products including semaglutide and advised that certain products are unapproved new drugs and misbranded in violation of sections 505(a), 502(f)(1), 301(a).", "citation_tag": "[2]" }, { "item_type": "court_docket", "title": "GLP-1 RAs NAION Products Liability Litigation (E.D. Pa.)", "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "date": "2025-12-15", "themes": [ "THEME_PRODUCT_LIABILITY", "THEME_FAILURE_TO_WARN" ], "relevance": "Shows public multidistrict product-liability activity involving GLP-1 receptor agonists; cited to distinguish manufacturer product-liability aggregation from this visit’s missing baseline HbA1c process concern [3].", "used_part": "Transfer order context from the Judicial Panel on Multidistrict Litigation consolidating GLP-1 RAs Non-Arteritic Anterior Ischemic Optic Neuropathy products liability actions in the Eastern District of Pennsylvania.", "citation_tag": "[3]" }, { "item_type": "enforcement_recall", "title": "FDA recall D-0393-2025: Cardinal Health Inc. (Wegovy)", "url": "https://api.fda.gov/drug/enforcement.json", "date": "", "themes": [ "THEME_REGULATORY_ENFORCEMENT", "THEME_PRODUCT_LIABILITY" ], "relevance": "Identifies a public Wegovy supply-chain temperature-abuse recall; relevant only as product-quality context for the same molecule, not as authority on clinic HbA1c baseline labs [6].", "used_part": "Wegovy (semaglutide) injection recalled for temperature abuse: product potentially exposed to temperatures outside labeled storage conditions due to a shipping error and inappropriately released after extended removal from refrigerated storage.", "citation_tag": "[6]" } ], "executive_summary": "This oversight brief addresses a new semaglutide (Wegovy/Ozempic) start in which baseline HbA1c is absent from structured labs and the visit note, while other labs (eGFR, ALT, TSH) are recorded. The supplied public corpus consists of manufacturer- and compounding-focused FDA warning letters, a GLP-1 product-liability MDL docket, related personal-injury docket activity, an older diabetes-drug opinion, and a Wegovy temperature-abuse recall; none states clinic-level baseline-HbA1c documentation standards or any settlement, verdict, or fine amounts tied to missing glycemic labs. Public authorities therefore supply only attenuated product- and supply-chain context, not a grounded malpractice exposure measure for this documentation gap. Risk signal from public records for this discrete visit concern is insufficient. No public dollar exposure figures are stated in the retrieved materials.", "director_summary": "This oversight brief addresses a new semaglutide (Wegovy/Ozempic) start in which baseline HbA1c is absent from structured labs and the visit note, while other labs (eGFR, ALT, TSH) are recorded. The supplied public corpus consists of manufacturer- and compounding-focused FDA warning letters, a GLP-1 product-liability MDL docket, related personal-injury docket activity, an older diabetes-drug opinion, and a Wegovy temperature-abuse recall; none states clinic-level baseline-HbA1c documentation standards or any settlement, verdict, or fine amounts tied to missing glycemic labs. Public authorities therefore supply only attenuated product- and supply-chain context, not a grounded malpractice exposure measure for this documentation gap. Risk signal from public records for this discrete visit concern is insufficient. No public dollar exposure figures are stated in the retrieved materials.", "report": { "matter": "Missing baseline HbA1c at new semaglutide (Wegovy/Ozempic) start", "scope": "Review limited to this visit’s clinical_brief, message, evidence, and note_excerpt regarding absent baseline HbA1c on a new GLP-1 start, together with the six public authorities in reference_context (FDA warning letters, GLP-1 NAION MDL and related docket, Seufert opinion, openFDA Wegovy recall). No clinic chart beyond the supplied excerpts; no external research.", "facts_considered": "Female patient, age 51. Medication documented as Wegovy/Ozempic (semaglutide) 0.5 mg weekly, flagged as a new start. Structured labs show hba1c_percent=null. Physician note lists Labs: eGFR 81, ALT 31, TSH 2.38, with no HbA1c value or order. Note excerpt states baseline HbA1c not documented at new start (eGFR on chart: 81). Clinical brief describes the new semaglutide start as otherwise well documented aside from missing baseline HbA1c.", "issue_presented": "Whether, for medical-director oversight, initiation of semaglutide without documented baseline HbA1c in labs or the note presents a process and documentation gap relative to expected new-start metabolic workup, and what limited light analogous public GLP-1 enforcement and product-liability records shed on that concern.", "analysis": "The clinical record as supplied shows a clear documentation omission: a new weekly semaglutide start without any baseline HbA1c in structured data or free-text labs, despite concurrent recording of renal and other labs. That gap is a screening and labs-process issue internal to the visit workup. It is not, on these materials, a product-defect, compounding, or manufacturing fact pattern.\n\nReference_context authorities do not directly address clinic obligations to obtain or document baseline HbA1c before GLP-1 initiation. The FDA warning letter to GLP-1 Solution concerns website offers of compounded and unapproved GLP-1-related products and misbranding under the FDCA [2]. The Harbin Jixianglong letter addresses foreign manufacturing CGMP deviations [1]. The openFDA entry describes a Cardinal Health distribution temperature-abuse recall of Wegovy pens [6]. These speak to supply-chain and compounding enforcement posture, not to baseline glycemic lab documentation at a prescribing visit.\n\nDocket materials reflect manufacturer-facing product-liability aggregation around GLP-1 receptor agonists, including NAION-related MDL transfer activity in the Eastern District of Pennsylvania [3] and a Novo Nordisk personal-injury docket [4]. The Seufert opinion is an older summary-judgment decision in diabetes-drug product litigation involving FDA-related evidence [5]. Manufacturer product-liability and patent or MDL structures are not the same as clinic malpractice or documentation negligence. No retrieved opinion or docket passage establishes a standard of care for baseline HbA1c at semaglutide start or quantifies clinic exposure for omitting that lab.\n\nAccordingly, public authorities provide general GLP-1 regulatory and litigation atmosphere only. They do not bridge to a grounded liability analysis of this missing baseline HbA1c. Oversight value remains in confirming whether HbA1c was obtained outside the chart or should be documented before ongoing titration—without treating public MDL or warning-letter activity as proof of fault on this visit.", "observations": [ "[1] Public FDA warning letters in the corpus target manufacturing CGMP deviations and online compounding/unapproved GLP-1 marketing, not prescriber baseline-lab documentation patterns.", "[2] Public docket activity includes multidistrict product-liability consolidation related to GLP-1 receptor agonists (NAION-focused) and individual manufacturer personal-injury filings; these are manufacturer-directed theories, distinct from clinic charting of HbA1c.", "[3] An openFDA enforcement recall in the corpus addresses Wegovy temperature abuse in distribution, illustrating supply-chain quality enforcement rather than clinical laboratory workup at initiation.", "[4] None of the retrieved public records states settlement, verdict, civil penalty, or fine amounts applicable to missing baseline HbA1c or analogous clinic documentation gaps." ], "limitations": "This memorandum does not prove that the clinic departed from the standard of care, that the patient was harmed, or that any claim has been or will be asserted. Public records cited do not contain clinic policies, full laboratory interfaces, outside records, or prescriber reasoning beyond the supplied note excerpt. They do not establish what HbA1c value existed, whether testing occurred off-chart, or any causal link to product-liability or FDA enforcement matters. No finding of liability, breach, or damages is made or implied.", "director_considerations": "Consider whether the chart should reflect a baseline HbA1c result, an order, or a brief notation if the value was obtained externally before continued titration. A directed chart review may confirm completeness of new-start metabolic labs already referenced in internal reasoning (HbA1c alongside documented eGFR). Documentation consistency between structured lab fields and the narrative note may warrant routine QA sampling on new GLP-1 starts. No treatment or legal disposition is recommended herein.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials frame manufacturer product-liability docket activity and FDA compounding/manufacturing/recall enforcement around GLP-1 products, which is only weakly analogous to a clinic missing-baseline-HbA1c documentation concern. No settlement, verdict, award, fine, or civil-penalty dollar figures appear in the supplied reference_context for this issue. Exposure discussion is therefore qualitative and attenuated; no clinic-level loss estimate is available or appropriate from these records.", "figures": [], "basis": "Analogy attempted only at the level of general GLP-1 regulatory and product-liability atmosphere from FDA warning letters [1][2], NAION MDL and Novo Nordisk docket activity [3][4], Seufert product-liability opinion [5], and Wegovy distribution recall [6]. No record supplies monetary dispositions tied to missing baseline labs or clinic documentation.", "confidence": "none", "transparency_note": "Retrieved records do not state any public settlement, verdict, fine, or civil-penalty amounts relevant to missing baseline HbA1c or clinic new-start lab documentation. figures is empty on that basis. Filing fees and invented ranges are not used. It is not known from this corpus whether analogous clinic claims exist, their volume, or any dollar outcomes." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:48:46.732Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/72147628/glucagon-like-peptide-1-receptor-agonists-glp-1-ras-non-arteritic/", "body": "Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (Streamlined Docket) v. ELI LILLY AND COMPANY\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:01-md-03163\nFiled: 2025-12-15\nCause: 28:1332 Diversity-Product Liability Parties: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) NON-ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY PRODUCTS LIABILITY LITIGATION Filing: Order — Case 2:25-md-03163-KSM Document 120 Filed 07/02/26 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA IN RE: GLUGAGON-LIKE : CIVIL ACTION PEPTIDE-1 RECEPTOR AGONISTS : (GLP-1 RAS) NON-ARTERITIC : ANTERIOR ISCHEMIC OPTIC : Filing: TRANSFER ORDER FROM THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION THAT ALL ACTIONS LISTED ON SCHEDULE A AND PENDING OUTSIDE THE EASTERN DISTRICT OF PENNSYLVANIA ARE TRANS" }, { "n": 4, "title": "Bjorklund v. Novo Nordisk A/S", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/68225362/bjorklund-v-novo-nordisk-as/", "body": "Bjorklund v. Novo Nordisk A/S\nCourt: District Court, E.D. Pennsylvania\nDocket: 2:24-cv-00533\nFiled: 2024-02-05\nCause: 28:1332 Diversity-Personal Injury Parties: ELI LILLY & CO; NOVO NORDISK A/S; Novo Nordisk U S Commercial Holdings Inc; Jaclyn Bjorklund; NOVO NORDISK INC.; NOVO NORDISK RESEARCH CENTER SEATTLE INC.; Novo Nordisk U S Holdings Inc; NOVO NORDISK NORTH AMERICA OPERATIONS A/S; Novo Nordisk Pharmaceutical Industries L P Filing: MEMORANDUM in Opposition re 73 MOTION to Dismiss for Lack of Jurisdiction or in the Alternative to Dismiss Plaintiff's Express Warranty Claim Pursuant to Rule 12(b)(6) MOTION to Dismiss For Failure to State a Claim filed by Jaclyn Bjorklund. (Attachments: # 1 Exhibit Exhibit List, # 2 Exhibit 1- Plaintiffs Declaration, # 3 Exhibit 2- Novo Nordisk A/S Company Profile, Bloomberg, # 4 Exhibit 3- Novo Nordisk A/S, 2022 Annual Report, # 5 Exhibit 4- Novo List" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "FDA recall D-0393-2025: Cardinal Health Inc.", "source": "enforcement_recall", "themes": [], "url": "https://api.fda.gov/drug/enforcement.json", "body": "FDA recall D-0393-2025: Cardinal Health Inc.\nWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. Reason: Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution center. More specifically, product was removed from refrigerated storage for an extended period of time and inappropriately released." } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } }, { "id": "SYN-0063", "priority": "medium", "title": "Informed consent not documented", "full_message": "New GLP-1 start without documented informed consent.", "patient_label": "Female, 54", "visit_date": "2026-07-08", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly", "flag_code": "E_NO_CONSENT", "rule_id": "R10", "rulebook": "guideline", "rulebook_label": "Society guideline / intake standard", "source_cite": "Informed-consent standard for chronic injectable therapy.", "guideline_quote": "Informed-consent standard for chronic injectable therapy.", "source_snippet": "Informed consent for new GLP-1 start: not documented.", "evidence_field": "Agent evidence", "evidence_raw": "doctor_report.informed_consent_documented = False at new start", "evidence_label": "doctor_report.informed_consent_documented = False at new start", "why": "New GLP-1 start without documented informed consent.", "note": "Encounter SYN-0063\nPatient: Female, 54 · BMI 27.0\nComorbidities: dyslipidemia, OSA\nContraindication history: personal MTC no; family MTC no; MEN2 no; pancreatitis no; MEN2 screen documented yes\nPregnancy status documented: yes\nMedication: Zepbound / Mounjaro (tirzepatide), 2.5 mg weekly (new start)\nLabs: HbA1c 5.4; eGFR 72\nFollow-up scheduled: yes\nInformed consent documented: no\nCompounded disclosure documented: yes\n\nClinician note\nNew-start visit. 54yo F on GLP-1 for weight management, BMI 27.0. On Zepbound (tirzepatide) 2.5 mg weekly. Initiating therapy today. Screened for personal/family history of medullary thyroid carcinoma and MEN2. Pregnancy status reviewed; not pregnant, contraception discussed. Prior weight-loss attempts (diet, activity, prior pharmacotherapy) documented. Labs: HbA1c 5.4%, eGFR 72, ALT 31, TSH 1.57. No new GI symptoms reported. Follow-up scheduled in 28 days.\n\nAssessment\nObesity, on GLP-1 therapy for weight management.\n\nPlan\nContinue per titration schedule. Labs reviewed. Follow-up scheduled.", "status": "pending", "xai": { "detector": "rules", "model": "composer-2.5", "run_at": "2026-07-20T19:09:50.958Z", "independent_summary": "Documentation and plan appear protocol-concordant for a new tirzepatide start in an overweight patient with weight-related comorbidities.", "reasoning_trace": [ "Observed: 54-year-old female, BMI 27.0 with dyslipidemia and OSA; new-start tirzepatide (Zepbound) 2.5 mg weekly; structured labs include HbA1c 5.4% and eGFR 72.", "Eligibility: BMI 27 with weight-related comorbidities meets FDA weight-management threshold [2][3]; no insulin, sulfonylurea, or compounded product documented.", "Safety screens: structured history negative for MTC/MEN2/pancreatitis; note documents MTC/MEN2 screening, pregnancy review (not pregnant), and prior weight-loss attempts.", "Monitoring/plan: baseline HbA1c and renal function present; follow-up scheduled in 28 days at starting dose with no dose escalation.", "Not flagged: no chart evidence for eating disorder history, pancreatitis, insulin/sulfonylurea interaction, rapid titration, or missing baseline labs; assessment wording 'Obesity' at BMI 27 has no matching error_code.", "reference_context used only to confirm eligibility criteria [2][3]; no omissions identified requiring director review." ], "reasoning_steps": [ "Observed: doctor_report.informed_consent_documented = False at new start", "Concern: New GLP-1 start without documented informed consent.", "Conclusion: Director review recommended before disposition." ], "agent_message": "New GLP-1 start without documented informed consent.", "agent_evidence": "doctor_report.informed_consent_documented = False at new start", "kb_excerpts": [ { "n": 1, "title": "Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. (glp1-safety §abstract; DOI 10.7759/cureus.107202)", "body": "Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by improving glycemic control, promoting clinically meaningful weight loss, and reducing major adverse cardiovascular events (MACE) in selected..." }, { "n": 2, "title": "FDA label (tirzepatide) - Indications And Usage (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "INDICATIONS AND USAGE ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid..." }, { "n": 3, "title": "FDA label (tirzepatide) - Indications And Usage [part 2] (FDA label §indications_and_usage; FDA SPL (Zepbound, ZEPBOUND, Zepbound KwikPen), set 487cd7e7-434c-4925-99fa-aa80b1cc776b)", "body": "ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with..." } ], "kb_cited": [], "all_agent_flags": [], "rules_codes": [ "E_NO_CONSENT" ] }, "liability_pack": { "flag": { "request_id": "SYN-0063", "error_code": "E_NO_CONSENT", "message": "New GLP-1 start without documented informed consent.", "evidence": "doctor_report.informed_consent_documented = False at new start", "note_excerpt": "Informed consent for new GLP-1 start: not documented.", "clinical_brief": "Documentation and plan appear protocol-concordant for a new tirzepatide start in an overweight patient with weight-related comorbidities.", "clinical_title": "Informed consent not documented", "medication": "Zepbound / Mounjaro (tirzepatide) 2.5 mg weekly" }, "liability": { "request_id": "SYN-0063", "related": [], "executive_summary": "This oversight brief concerns a new tirzepatide (Zepbound/Mounjaro) start in a 54-year-old female where the clinical record flags that informed consent was not documented. The supplied note indicates the remainder of the plan appears protocol-concordant for an overweight patient with weight-related comorbidities. Public authorities in the retrieved corpus address compounding, manufacturing, trademark, and manufacturer product-liability themes, not clinic-level informed-consent documentation for GLP-1 initiation. No public settlement, verdict, or fine amounts applicable to this documentation concern appear in the reference materials. Public-record support for calibrating liability exposure on this specific process gap is therefore insufficient.", "director_summary": "This oversight brief concerns a new tirzepatide (Zepbound/Mounjaro) start in a 54-year-old female where the clinical record flags that informed consent was not documented. The supplied note indicates the remainder of the plan appears protocol-concordant for an overweight patient with weight-related comorbidities. Public authorities in the retrieved corpus address compounding, manufacturing, trademark, and manufacturer product-liability themes, not clinic-level informed-consent documentation for GLP-1 initiation. No public settlement, verdict, or fine amounts applicable to this documentation concern appear in the reference materials. Public-record support for calibrating liability exposure on this specific process gap is therefore insufficient.", "report": { "matter": "Missing informed-consent documentation — new tirzepatide (GLP-1) start", "scope": "Review limited to this visit’s clinical concern (informed consent not documented at new GLP-1 start) and the vetted public reference_context items only (FDA warning letters, selected dockets/opinions). No clinic file, policy manual, or external research was reviewed.", "facts_considered": "Patient labeled female, age 54. Medication: Zepbound/Mounjaro (tirzepatide) 2.5 mg weekly as a new start. Clinical brief states documentation and plan appear protocol-concordant for an overweight patient with weight-related comorbidities. Evidence flag: doctor_report.informed_consent_documented = False at new start. Note excerpt: “Informed consent for new GLP-1 start: not documented.” Message characterizes the visit as a new GLP-1 start without documented informed consent.", "issue_presented": "Whether absence of documented informed consent at initiation of tirzepatide presents a process and oversight gap relative to ordinary documentation expectations, and what—if anything—the retrieved public authorities contribute to assessing that gap.", "analysis": "The clinical concern is narrow and process-oriented: a new tirzepatide start with an explicit record indication that informed consent was not documented, while other elements of the plan are described as protocol-concordant. Informed-consent documentation is a foundational doctor–patient and risk-communication control; its absence in the chart is the sole flagged deviation supplied here.\n\nThe public corpus provided does not contain court opinions, dockets, or enforcement letters that analyze clinic duties to document informed consent before prescribing tirzepatide or other GLP-1 agents. Item [2] addresses an overseas website offering compounded retatrutide, semaglutide, and tirzepatide as unapproved and misbranded drugs—an FDA regulatory-enforcement posture on compounding and interstate distribution, not on consent charting at a treating clinic. Items [3] and [4] are trademark infringement actions by Novo Nordisk against weight-loss clinics, which do not speak to consent documentation. Item [1] concerns CGMP deviations at a foreign drug manufacturer. Item [5] is a manufacturer product-liability summary-judgment decision in an incretin-related litigation posture, not a clinic malpractice or consent case. Item [6] is a state appellate matter involving a health care authority and does not, on the supplied excerpt, address informed consent for GLP-1 therapy.\n\nAccordingly, while missing consent documentation is a recognized process vulnerability in clinical oversight generally, the cited public authorities cannot be reliably mapped to this visit’s documentation gap. No analogy from those records supports a calibrated public-exposure conclusion specific to undocumented consent for this tirzepatide start.", "observations": [ "[1] Retrieved FDA warning letters in the corpus focus on manufacturing CGMP and on compounded/unapproved GLP-1-related products offered online, not on clinic informed-consent documentation practices.", "[2] Public dockets supplied against weight-loss clinics center on trademark/brand enforcement by a manufacturer, which is a distinct theory from failure to document patient consent.", "[3] Manufacturer product-liability opinion material in the corpus does not establish standards or outcomes for clinic-level consent charting on a new tirzepatide prescription.", "[4] No public dollar figures (settlements, verdicts, fines, or civil penalties) tied to missing informed-consent documentation for GLP-1 starts appear in the supplied reference_context." ], "limitations": "This memorandum does not prove that the clinic failed to obtain consent, that consent was not discussed, or that any statute, regulation, or standard of care was breached. It does not assess the completeness of the full medical record, verbal consent practices, EHR configuration, or institutional consent forms. Public records cited do not adjudicate this visit, this clinician, or this organization. Manufacturer, compounding, and trademark matters are not findings about this clinic’s malpractice exposure. No prediction of suit, liability, or loss is made.", "director_considerations": "Consider a targeted chart audit confirming whether a signed or attested informed-consent artifact exists outside the flagged field for this new tirzepatide start, and whether the EHR consent indicator is required before first dispense or injection teaching. Review whether standard risk topics for tirzepatide (e.g., labeled risks, alternatives, uncertainty) are captured in a reusable template when consent is recorded. Ensure any remediation is documentation- and process-focused and does not alter clinical decision-making solely on the basis of this public-record brief.", "risk_band": "insufficient" }, "exposure": { "summary": "Retrieved public materials do not state settlement, verdict, award, fine, or civil-penalty amounts for missing informed-consent documentation in connection with clinic initiation of tirzepatide or other GLP-1 therapy. Analogous public items concern compounding enforcement, foreign manufacturing, trademark suits against weight-loss clinics, and manufacturer product-liability litigation—not consent charting. Qualitative public exposure specific to this documentation concern therefore cannot be grounded in the supplied corpus.", "figures": [], "basis": "No applicable public dollar figures in reference_context; residual items ([1]–[6]) are enforcement, trademark, or manufacturer-product authorities without stated damages tied to informed-consent documentation.", "confidence": "none", "transparency_note": "Retrieved records do not state public settlement, verdict, or fine amounts for this concern. No figure is presented as this clinic’s expected loss. Filing fees and unrelated case captions were not used as exposure estimates." }, "disclaimer": "Not legal advice. Public enforcement/litigation context only. For in-house legal / compliance review. RubikMD does not predict lawsuit outcomes.", "model": "x-ai/grok-4.5", "harness": "openrouter-direct", "run_at": "2026-07-21T07:48:32.708Z", "used_context": true }, "retrieval_excerpts": [ { "n": 1, "title": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026", "body": "Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026 | FDA\nMore Warning Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-73 Product: Drugs Recipient: Recipient Name Mr. Guo Qing Leng Recipient Title President and General Manager Harbin Jixianglong Biotech Co., Ltd. North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-73 May 1, 2026 Dear Mr. Leng: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Harbin Jixianglong Biotech Co., Ltd., FEI 3024038751, at North of Baoan Road, East of Changqing Street, Liminzhen Hulan District, Harbin, Heilongjiang, from November 3 to 7, 2025. This warning letter summarizes significant deviations from Current Good Manufac" }, { "n": 2, "title": "GLP-1 Solution - 715883 - 09/09/2025 | FDA", "source": "warning_letter", "themes": [], "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025", "body": "GLP-1 Solution - 715883 - 09/09/2025 | FDA\nMore Warning Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: GLP-1 Solution 785 15h Street, Office 478 81566 Berlin Germany sales@glp1solution.store Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 GLP-1 Solution: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide. 1 As described below, your retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a), 502(f)(1), 301(a) " }, { "n": 3, "title": "Novo Nordisk A/S v. New England Weight Loss, LLC", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/69873291/novo-nordisk-as-v-new-england-weight-loss-llc/", "body": "Novo Nordisk A/S v. New England Weight Loss, LLC\nCourt: District Court, D. New Hampshire\nDocket: 1:25-cv-00141\nFiled: 2025-04-10\nCause: 15:1051 Trademark Infringement Parties: Novo Nordisk A/S; New England Weight Loss, LLC Filing: Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 11 Filed 10/17/25 Page 1 of 21 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 1:25-cv-00141-SE-AJ New England Weight Loss, LLC REPORT AND RECOMMENDATION Plaintiffs, Novo Nordisk A/S and Novo No Filing: Complaint - New Case Filing: Order on Motion for Default Judgment AND Order on Report and Recommendation — Case 1:25-cv-00141-SE-AJ Document 12 Filed 11/18/25 Page 1 of 2 UNITED STATES DISTRICT COURT DISTRICT OF NEW HAMPSHIRE Novo Nordisk A/S, et al. v. Case No. 25-cv-141-SE-AJ New England Weight Loss, LLC ORDER N\nReport and Recommendation: Case 1:25" }, { "n": 4, "title": "Novo Nordisk A/S v. Champion Health and Wellness Clinics LLC", "source": "court_docket", "themes": [], "url": "https://www.courtlistener.com/docket/67511859/novo-nordisk-as-v-champion-health-and-wellness-clinics-llc/", "body": "Novo Nordisk A/S v. Champion Health and Wellness Clinics LLC\nCourt: District Court, S.D. Texas\nDocket: 4:23-cv-02246\nFiled: 2023-06-20\nCause: 28:1331 Fed. Question: Trademark Parties: Novo Nordisk Inc.; Novo Nordisk A/S; Champion Health and Wellness Clinics LLC Filing: Complaint AND Complaint — Case 4:23-cv-02246 Document 1 Filed on 06/20/23 in TXSD Page 1 of 19 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF TEXAS NOVO NORDISK A/S AND NOVO NORDISK INC., Plaintiffs, Case No. _______________ v. CHAMPION HEALTH AND WELLNESS CLINICS LLC, Defendant. Filing: Answer to Complaint — UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION NOVO NORDISK A/S AND NOVO § NORDISK INC., § § CIVIL ACTION NO. 4:23-cv-02246 Plaintiffs, § v. Filing: Exhibit B — Case 4:23-cv-02246 Document 1-2 Filed on 06/20/23 in TXSD Page 1 of 12 EXHIBIT B ela ala c | CHAMPION Health aid Welluies" }, { "n": 5, "title": "Seufert v. Merck Sharp & Dohme Corp.", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/7320392/seufert-v-merck-sharp-dohme-corp/", "body": "Seufert v. Merck Sharp & Dohme Corp.\nCourt: District Court, S.D. California\nDocket: Case No.: 13cv2169 AJB (MDD); Seufert: 13cv2169; Lara: 13cv2928; McDaniel: 13cv3191; Gaines: 14cv0056; Marble: 14cv0611; Stovall: 14cv1612; Heindl: 14cv1973; Blazer: 15cv1149; Gibson: 15cv1340; Deihl: 15cv1435; Copeland: 15cv1884; Matthews: 15cv2190; Elosegui: 15cv198\nFiled: 2016-05-11\nCitation: 187 F. Supp. 3d 1163; 2016 U.S. Dist. LEXIS 91837; 2016 WL 3369512\nORDER GRANTING DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT Hon. Anthony J. Battaglia, United States District Judge I. INTRODUCTION On February 27, 2014, the FDA published the following in the New England Journal of Medicine'. With approximately 25.8 million diabetic patients in the United States and 33 million in the European Union alone, the grow" }, { "n": 6, "title": "Jeannette Simonton, V. Washington State Health Care Authority", "source": "court_opinion", "themes": [], "url": "https://www.courtlistener.com/opinion/10852801/jeannette-simonton-v-washington-state-health-care-authority/", "body": "Jeannette Simonton, V. Washington State Health Care Authority\nCourt: Court of Appeals of Washington\nDocket: 86988-4\nFiled: 2026-05-04\nIN THE COURT OF APPEALS OF THE STATE OF WASHINGTON JEANNETTE SIMONTON and RYAN KELSO, each on their own behalf and No. 86988-4-I on behalf of similarly situated others, DIVISION ONE Appellants, PUBLISHED OPINION v. WASHINGTON STATE HEALTH CARE AUTHORITY; and SUE BIRCH, director of the Washington State Health Care Authority and chair of t" } ], "live": true, "preloaded": true, "harness": "openrouter-direct", "model": "x-ai/grok-4.5" } } ] }